

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037274 A2

- (51) International Patent Classification⁷: A61K (74) Agents: MANN, Jeffry, S. et al.; Townsend Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).
- (21) International Application Number: PCT/US02/35172
- (22) International Filing Date: 1 November 2002 (01.11.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/335,958 1 November 2001 (01.11.2001) US
- (71) Applicant (for all designated States except US): ICA-GEN, INC. [US/US]; Suite 460, 4222 Emperor Boulevard, Durham, NC 27703 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ATKINSON, Robert, Nelson [US/US]; 11908 Radner Way, Raleigh, NC 27613 (US). GROSS, Michael, Francis [US/US]; 6200 Chesden Drive, Durham, NC 27713 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: PYRAZOLE-AMIDES AND-SULFONAMIDES

A			B		
compound #	Structure	MW			
790		405	1126		447
791		494	1128		475
831		482	1129		487
1043		516	1149		459
1047		459	1150		487
1048		467			
1124		534			
1125		461			

(57) Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazole-amides and -sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.

WO 03/037274 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PYRAZOLE-AMIDES AND -SULFONAMIDES

CROSS-REFERENCES TO RELATED APPLICATIONS

This is a non-provisional filing of United States Provisional Patent Application Number 60/335,958, filed on November 1, 2001, the disclosure of which is
5 incorporated herein by reference in its entirety for all purposes.

FIELD OF THE INVENTION

This invention relates to the use of certain pyrazole amide and pyrazole sulfonamide compounds as sodium channel inhibitors and to the treatment of neuropathic pain by the inhibition of sodium channels. Additionally, this invention relates to novel
10 pyrazole-based compounds that are useful as sodium channel inhibitors.

BACKGROUND OF THE INVENTION

Sodium channel-blocking agents have been reported to be effective in the treatment of various disease states, and have found particular use as local anesthetics and
15 in the treatment of cardiac arrhythmias. It has also been reported that sodium channel-blocking agents may also be useful in the treatment of pain, including neuropathic pain; see, for example, Tanelian *et al. Pain Forum*. 4(2), 75-80 (1995). Preclinical evidence demonstrates that sodium channel-blocking agents selectively suppress abnormal ectopic neural firing in injured peripheral and central neurons, and it is via this mechanism that
20 they are believed to be useful for relieving pain. Consistent with this hypothesis, it has been shown that sodium channels accumulate in the peripheral nerve at sites of axonal injury (Devor *et al. J. Neurosci.* 132: 1976 (1993)). Alterations in either the level of expression or distribution of sodium channels within an injured nerve, therefore, have a major influence on the pathophysiology of pain associated with this type of trauma.

25 An increasing body of evidence suggests that a voltage-dependent, tetrodotoxin (TTX)-resistant Na channel, PN3 (Na_v1.8), may play a key role in sensitization in neuropathic pain states. Neuropathic pain can be described as pain associated with damage or permanent alteration of the peripheral or central nervous system. Clinical manifestations of neuropathic pain include a sensation of burning or
30 electric shock, feelings of bodily distortion, allodynia and hyperalgesia.

PN3 is a member of a family of voltage-gated sodium channel alpha subunits. Names for this family include SCN, SCNA, and Na_vx.x. There are currently 10

known members falling into two subfamilies Na_v1 (all but SCN6A) and Na_v2 (SCN6A). The human channel was cloned by Rabert *et al.* (*Pain* 78(2): 107-114 (1998)). PN3 of other species has also been cloned. See, for example, Chen *et al.*, *Gene* 202(1-2), 7-14 (1997); Souslova *et al.*, *Genomics* 41(2), 201-209 (1997); Akopian *et al.*, *Nature* 5 379(6562), 257-262 (1996).

PN3-null mutant mice exhibit a pronounced analgesia to mechanical noxious stimuli (Akopian A.N. *et al.*, *Nature Neurosci.*, 2(6): 541-548 (1999)). Selective “knock down” of PN3 protein in the rat dorsal root ganglion with specific antisense oligodeoxynucleotides prevents hyperalgesia and allodynia caused by either chronic 10 nerve or tissue injury (Porreca *et al.*, *Proc. Nat. Acad. Sci., USA*, 96: 7640-7644 (1999)). The biophysical properties of PN3 make it ideally suited to sustain repetitive firing of sensory neurons at the depolarized potentials characteristic of injured peripheral nerves. In both human and animal models of neuropathic pain, there is an increased expression of PN3 at the site of peripheral nerve injury (Clare *et al.*, *DDT* 5: 506-519 (2000); Coward *et al.*, *Pain* 85: 41-50 (2000)). 15

Patients with neuropathic pain do not respond to non-steroidal anti-inflammatory drugs (NSAIDS) and resistance or insensitivity to opiates is common. Most other treatments have limited efficacy or undesirable side effects. Mannion *et al.*, *Lancet*, 353: 1959-1964 (1999) from the Department of Anesthesia and Critical Care, 20 Massachusetts General Hospital and Harvard Medical School wrote: “There is no treatment to prevent the development of neuropathic pain, nor to adequately, predictably and specifically control established neuropathic pain.”

PN3 is a promising molecular target for the treatment of neuropathic pain. One of the most attractive features of PN3 is the highly restricted and peripheral nature of 25 its expression. Antisense studies have revealed no overt (particularly CNS-related) adverse effects, consistent with the localized, peripheral distribution of the channel (Novakovic *et al.*, *J. Neurosci.*, 18(6): 2174-2187 (1998)). Additionally, the high activation threshold of PN3 suggests that the channel may be relatively uninvolved in normal nociception. These properties of PN3 present the possibility that selective 30 blockade of this particular voltage-gated sodium channel (VGSC) may offer effective pain relief without the significant side effect liability normally associated with more promiscuous VGSC blocking drugs. The compounds of the invention are potent inhibitors of PN3 channels.

Ohkawa *et al.* have described a class of cyclic ethers that are of use as sodium channel blockers (U.S. Patent No. 6,172,085).

Currently, gabapentin is the market leading treatment for neuropathic pain. As with epilepsy, its mechanism of action for pain is unknown. It is a very safe, easy to use drug, which contributes to its sales. Efficacy for neuropathic pain is not impressive, as few as only 30% of patients respond to gabapentin treatment. Carbamazepine is also used to treat neuropathic pain.

In view of the limited number of agents presently available and the low levels of efficacy of the available agents, there is a pressing need for compounds that are potent, specific inhibitors of ion channels implicated in neuropathic pain. The present invention provides such compounds, methods of using them, and compositions that include the compounds.


SUMMARY OF THE INVENTION

It has now been discovered that pyrazole-amides and -sulfonamides are potent inhibitors of sodium channels. In the discussion that follows, the invention is exemplified by reference to the inhibition of sodium channels that are localized in the peripheral nervous system, and in particular those inhibitors that are selective inhibitors of PN3, and are useful for treating neuropathic pain through the inhibition of sodium ion flux through channels that include the PN3 subunit. The focus of the discussion is for clarity of illustration only.

The compounds and methods of the present invention are useful for treating diseases in which blocking or inhibiting one or more PN3 ion channel provides relief from the disease. Of particular interest is the use of the compounds and methods of the invention for treating pain and central or peripheral nervous system disorders. The present invention is of use for treating both inflammatory and neuropathic pain.

The present invention provides compounds which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides compounds, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain.

In one aspect, the present invention provides compounds according to Formula I:




(I)

or a pharmaceutically acceptable salt thereof. In Formula I, the symbols R^1 and R^3 are independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl. The symbol

5 R^2 represents hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, or heteroaryl(C₁-C₄)alkyl;

The symbol Y is a member selected from :



wherein X is a member selected from O, S and NR^8 . The symbol R^8 represents hydrogen,

10 cyano, nitro, alkyl, acyl, aryl or SO_2R^9 . R^9 is selected from alkyl, aryl, heteroaryl and heterocycloalkyl. The symbols R^4 and R^5 independently represent hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl, with the proviso that if R^4 is hydrogen, R^5 is not hydrogen. R^4 and R^5 taken together with the nitrogen atom to which

15 they are attached optionally form a 4- to 8-membered heterocycloalkyl ring. The symbol R^6 represents hydrogen, (C₁-C₆)alkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl or (C₁-C₆)heteroalkyl. R^7 is selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-C₈)heterocycloalkyl and amino(C₁-C₅)alkyl, and

20 and R^6 and R^7 together with the atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.

In another aspect, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound provided above.

25 In yet another aspect, the present invention provides a method for inhibiting ion flux through voltage dependent sodium channels, comprising contacting a cell containing the target ion channels with a compound that comprises a pyrazolyl moiety, such as the compounds of Formula I.

In still another aspect, the present invention provides a method for the

30 treatment of diseases through inhibition of ion flux through voltage dependent sodium channels, the method comprising treating the host with an effective amount of a sodium

channel inhibiting compound comprising a pyrazolyl moiety, such as a compound of Formula I.

Other objects, advantages and embodiments of the invention will be apparent from review of the detailed description that follows.

5

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a table displaying structures of representative compounds of the invention.

DETAILED DESCRIPTION OF THE INVENTION AND THE PREFERRED EMBODIMENTS

10

Definitions:

The term "pain" refers to all categories of pain, including pain that is described in terms of stimulus or nerve response, *e.g.*, somatic pain (normal nerve response to a noxious stimulus) and neuropathic pain (abnormal response of a injured or altered sensory pathway, often without clear noxious input); pain that is categorized temporally, *e.g.*, chronic pain and acute pain; pain that is categorized in terms of its severity, *e.g.*, mild, moderate, or severe; and pain that is a symptom or a result of a disease state or syndrome, *e.g.*, inflammatory pain, cancer pain, AIDS pain, arthropathy, migraine, trigeminal neuralgia, cardiac ischaemia, and diabetic neuropathy (*see, e.g., Harrison's Principles of Internal Medicine*, pp. 93-98 (Wilson *et al.*, eds., 12th ed. 1991); Williams *et al.*, *J. of Medicinal Chem.* 42:1481-1485 (1999), herein each incorporated by reference in their entirety).

"Somatic" pain, as described above, refers to a normal nerve response to a noxious stimulus such as injury or illness, *e.g.*, trauma, burn, infection, inflammation, or disease process such as cancer, and includes both cutaneous pain (*e.g.*, skin, muscle or joint derived) and visceral pain (*e.g.*, organ derived).

"Neuropathic" pain, as described above, refers to pain resulting from injury to or chronic changes in peripheral and/or central sensory pathways, where the pain often occurs or persists without an obvious noxious input.

"Biological medium," as used herein refers to both *in vitro* and *in vivo* biological milieus. Exemplary *in vitro* "biological media" include, but are not limited to, cell culture, tissue culture, homogenates, plasma and blood. *In vivo* applications are generally performed in mammals, preferably humans.

“Compound of the invention,” as used herein refers to the compounds discussed herein, pharmaceutically acceptable salts and prodrugs of these compounds.

“Inhibiting” and “blocking,” are used interchangeably herein to refer to the partial or full blockade of a PN3 channel by a compound of the invention, which leads to a decrease in ion flux either into or out of a cell in which a PN3 channel is found.

Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents which would result from writing the structure from right to left, *e.g.*, $-\text{CH}_2\text{O}-$ is intended to also recite $-\text{OCH}_2-$; $-\text{NHS}(\text{O})_2-$ is also intended to represent $-\text{S}(\text{O})_2\text{HN}-$, *etc.*

The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (*i.e.* $\text{C}_1\text{-C}_{10}$ means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *t*-butyl, isobutyl, *sec*-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, *n*-pentyl, *n*-hexyl, *n*-heptyl, *n*-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butylnyl, and the higher homologs and isomers. The term “alkyl,” unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.” Alkyl groups, which are limited to hydrocarbon groups are termed “homoalkyl”.

The term “alkylene” by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, and further includes those groups described below as “heteroalkylene.” Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.

The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.

The term "amino" refers to -NRR' in which R and R' are members
5 independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl.

The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon
10 radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the
15 remainder of the molecule. Examples include, but are not limited to, -CH₂-CH₂-O-CH₃, -CH₂-CH₂-NH-CH₃, -CH₂-CH₂-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃, -CH₂-CH₂-S(O)-CH₃, -CH₂-CH₂-S(O)₂-CH₃, -CH=CH-O-CH₃, -Si(CH₃)₃, -CH₂-CH=N-OCH₃, and -CH=CH-N(CH₃)-CH₃. Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Similarly, the term "heteroalkylene" by itself or as part
20 of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH₂-CH₂-S-CH₂-CH₂- and -CH₂-S-CH₂-CH₂-NH-CH₂-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking
25 group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)₂R' represents both -C(O)₂R' and -R'C(O)₂-.

In general, an "acyl" or "acyl substituent" is also selected from the group set forth above. As used herein, the term "acyl substituent" refers to groups attached to, and fulfilling the valence of a carbonyl carbon that is either directly or indirectly attached
30 to the nucleus of the compounds of the present invention.

The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the

molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, 1-pyrrolidine, 2-pyrrolidine, 3-pyrrolidine and the like.

The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C₁-C₄)alkyl" is meant to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazole, 3-pyrazolyl, 4-pyrazole, 5-pyrazole, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 2-benzthiazole, 2-benzoxazole, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxaliny, 5-quinoxaliny, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

For brevity, the term "aryl" when used in combination with other terms (*e.g.*, aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (*e.g.*, benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (*e.g.*, a methylene group) has been

replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).

Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl" and "heteroaryl") include both substituted and unsubstituted forms of the indicated radical. Preferred substituents
 5 for each type of radical are provided below.

Substituents for the alkyl, and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are generally referred to as "alkyl substituents" and "heteroalkyl substituents," respectively, and they can be one or more of
 10 a variety of groups selected from, but not limited to: -hydrogen, -OR', =O, =NR''', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR'C(O)R'', -NR'''-C(O)NR'R'', -NR'C(O)₂R'', -NR'''-C(NR'R'')=NR''', -NR'''-C(NR'R'')=NR''', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NR'SO₂R'', -NR'''SO₂NR'R'' -CN, -R' and -NO₂ in a number ranging from zero to
 15 (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'', R''' each preferably independently refer to hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, (e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups), substituted or unsubstituted heteroaryl and substituted or unsubstituted arylalkyl. R''' refers to
 20 hydrogen, alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, -CN, -NO₂ and -S(O)₂R'. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R''' groups when more than one of these groups is present. When R' and R'' are attached to
 25 the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such
 30 as haloalkyl (e.g., -CF₃ and -CH₂CF₃) and acyl (e.g., -C(O)CH₃, -C(O)CF₃, -C(O)CH₂OCH₃, and the like).

Similar to the substituents described for the alkyl radical, the aryl substituents and heteroaryl substituents are generally referred to as "aryl substituents" and "heteroaryl substituents," respectively and are varied and selected from, for example:

hydrogen, -OR', -C=NR'''NR'R'', -NR'''SO₂NR'R'', -NR'R'', -SR', -halogen, -
 SiR'R'R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R',
 -NR'''-C(O)NR'R'', -NR''C(O)₂R', -NR'''-C(NR'R'')=NR''', -S(O)R', -S(O)₂R', -
 S(O)₂NR'R'', -NR''SO₂R', -CN and -NO₂, -R', -N₃, -CH(Ph)₂, fluoro(C₁-C₄)alkoxy, and
 5 fluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences
 on the aromatic ring system; and where R', R'' and R''' each preferably independently
 refer to hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted
 heteroalkyl, substituted or unsubstituted aryl, (e.g., aryl substituted with 1-3 halogens,
 substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups), substituted or
 10 unsubstituted heteroaryl and substituted or unsubstituted arylalkyl. R''' refers to
 hydrogen, alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl,
 substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, -CN, -NO₂
 and -S(O)₂R'. When a compound of the invention includes more than one R group, for
 example, each of the R groups is independently selected as are each R', R'', R''' and R''''
 15 groups when more than one of these groups is present. When R' and R'' are attached to
 the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or
 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-
 pyrrolidinyl, 1-piperidinyl, 1-piperazinyl and 4-morpholinyl.

Two of the aryl substituents on adjacent atoms of the aryl or heteroaryl
 20 ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR')_q-U-,
 wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an
 integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl
 or heteroaryl ring may optionally be replaced with a substituent of the formula -
 A-(CH₂)_r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)₂-,
 25 -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds
 of the new ring so formed may optionally be replaced with a double bond. Alternatively,
 two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be
 replaced with a substituent of the formula -(CRR')_s-X-(CR'R'')_d-, where s and d are
 independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -
 30 S(O)₂NR'-. The substituents R, R', R'' and R''' are preferably independently selected
 from hydrogen or substituted or unsubstituted (C₁-C₆)alkyl.

As used herein, the term "heteroatom" includes oxygen (O), nitrogen (N),
 sulfur (S) and silicon (Si).

The symbol "R" is a general abbreviation that represents a substituent group that is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl groups.

5 The symbol ~~, whether utilized as a bond or displayed perpendicular to a bond indicates the point at which the displayed moiety is attached to the remainder of the molecule, solid support, etc.

 The term "pharmaceutically acceptable salts" includes salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of
10 the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic
15 amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric,
20 carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and
25 the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (*see*, for example, Berge *et al.*, "Pharmaceutical Salts", *Journal of Pharmaceutical Science*, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

30 The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the

salts are equivalent to the parent form of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.


Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

Description of the Embodiments

I. INHIBITORS OF VOLTAGE-DEPENDENT SODIUM CHANNELS


In one aspect, the present invention provides compounds having the formula:



(I)

or a pharmaceutically acceptable salt thereof. In Formula I, the symbols R^1 and R^3 independently represent hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl. R^2 is a moiety selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl.

The symbol Y represents a member selected from:




wherein X is selected from O, S and NR^8 . The symbol R^8 represents hydrogen, cyano, nitro, alkyl, acyl, aryl or SO_2R^9 . R^9 is selected from alkyl, aryl, heteroaryl and heterocycloalkyl.

R^4 and R^5 are independently selected from hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl, with the proviso that if R^4 is hydrogen, R^5 is not hydrogen. R^4 and R^5 taken together with the nitrogen atom to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.


The symbol R^6 represents hydrogen, (C₁-C₆)alkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl or (C₁-C₆)heteroalkyl; and R^7 is selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-C₈)heterocycloalkyl and amino(C₁-C₅)alkyl. R^6 and R^7 together with the atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.

In a presently preferred embodiment Y is a member selected from:



in which R^4 , R^5 , R^6 , R^7 , and X are as described above.


In another exemplary embodiment, the invention provides a compound having a structure according to Formula II:



(II)


in which R¹, R², R³, and Y are as described above. In this embodiment, R¹ and R³ are preferably each independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl and (C₁-C₅)heteroalkyl. R² is preferably selected from aryl and heteroaryl; and X is preferably O.

In a further exemplary embodiment, R⁴ and R⁵ taken together with the nitrogen to which they are attached form a ring system such as that set forth below:



In another preferred embodiment, R³ is hydrogen; R⁴ is selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl and heteroaryl(C₁-C₄)alkyl; and R⁵ is selected from hydrogen or alkyl. Alternatively, R⁴ and R⁵ taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocycloalkyl ring.

In yet a further preferred embodiment, the invention provides a compound in which R⁴ is a member selected from:



wherein n is an integer from 0 to 4; and k is an integer from 1 to 3. The symbols R^{2a} and R^{2b} are independently selected from hydrogen and (C₁-C₄)alkyl, and R^{2a} and R^{2b} taken together with the carbon atom to which they are attached optionally form a 3- to 8-membered carbocyclic or heterocycloalkyl ring.

The symbol M represents a moiety that is selected from NR¹⁰, O and S, wherein R¹⁰ is selected from hydrogen, (C₁-C₆) alkyl, (C₁-C₈) heteroalkyl aryl, heteroaryl and (C₃-C₈) cycloalkyl. A, B, D, E and G are independently moieties selected from N, N-oxide and CR¹¹, with the proviso that at most three of A, B, D, E and G is N; and at most one of A, B, D, E and G is N-oxide.

R¹¹ is a member selected from hydrogen, halo, amino, hydroxy, cyano, nitro, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)heteroalkyl, aryl, heteroaryl, (C₃-C₈)heterocycloalkyl, alkoxy, acyl, -C(NR¹²)R¹³, -SO₂R¹⁵, -SO₂NR¹³R¹⁴, -NR¹²SOR¹⁵,


-NR¹²SO₂NR¹³R¹⁴, -NR¹²C(N-CN)NR¹³R¹⁴, -NR¹²C(N-SO₂R¹⁵)NR¹³R¹⁴, -NR¹²C(N-COR¹⁵)NR¹³R¹⁴, -CONR¹³R¹⁴, -NR¹²(C=CH-NO₂)NR¹³R¹⁴, -NR¹²CONR¹³R¹⁴, -NR¹²CO-OR¹⁵, -OCONR¹³R¹⁴, and R¹¹ and R^{2a} taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl group with the proviso that A is CR¹¹.

R^{11a} is selected from (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, (C₃-C₈)heterocycloalkyl, aryl and heteroaryl. The symbols R¹², R¹³ and R¹⁴ independently represent hydrogen, (C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, (C₃-C₈)heterocycloalkyl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino(C₁-C₄)alkyl and when R¹³ and R¹⁴ are attached to the same nitrogen atom, they are optionally combined to form a 5-, 6- or 7-membered ring.

R¹⁵ is selected from (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl and (C₃-C₈)heterocycloalkyl

When R⁴ has a cyclic structure set forth above, R¹ and R³ are preferably each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl and (C₁-C₅)heteroalkyl; and X is O. R² is a preferably a member selected from aryl or heteroaryl.

In yet another preferred embodiment, the invention provides a compound in which R⁴ has a structure according to Formula III:



(III).

In Formula III, W is preferably selected from S, SO or SO₂ or a single bond. SO₂ is presently most preferred. The symbol R¹⁵ represents a moiety selected from (C₁-C₄)alkyl, (C₁-C₆)alkenyl, (C₃-C₇)cycloalkyl, aryl, heteroaryl, (C₁-C₈)heteroalkyl, NR¹⁶R¹⁷. R¹⁶ and R¹⁷ are independently selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, (C₃-C₈)heterocycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino(C₁-C₄)alkyl, with the proviso that when R¹⁵ is amino W is SO₂;

The symbols T¹, T², T³ and T⁴ are each independently selected from hydrogen, halo, amino, cyano, nitro, (C₁-C₄)alkyl, (C₃-C₈)cycloalkyl, (C₁-C₄)haloalkyl, alkoxy, fluoro(C₁-C₄)alkoxy, (C₁-C₇)cycloalkyl, (C₁-C₇)heteroalkyl, aryl and heteroaryl.

T¹ and T² taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring. T² and T³ taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring. T³ and R¹⁵ taken together with the atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring. T⁴ and R¹⁵ taken together with the atoms to which they are attached optionally form a 4- to 8-membered carbocyclic or heterocycloalkyl ring.

In a preferred embodiment, R¹ and R³ are each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl or (C₁-C₅)heteroalkyl; and X is O. R² is preferably a member selected from aryl or heteroaryl.

Representative compounds of the invention are set forth in Example 24 and FIG. 1. Activities towards PN3 of selected compounds of the invention are provided in Table 1. The compound numbers in Table 1 are cross-referenced to the compound numbers set forth in the Example and figures.

Table 1

Compound #	Activity in Flux Assay
20	+++
23	++
39	+++
114	+
154	+++
323	+++
411	+++
414	+++
444	++
449	+++
480	+++
1054	+++
1175	++

(+++ 0.1-4 μ M; ++ 4.1-10 μ M; + 10.1-30 μ M)

Also within the scope of the present invention are compounds of the invention that are poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homologs of the compounds of the invention or reactive analogues thereof. The poly- and multi-valent species can be assembled from a single species or more than one species of the invention. For example, a dimeric construct can be "homodimeric" or "heterodimeric." Moreover, poly- and multi-valent constructs in which a compound of the invention or a reactive analogue thereof, is attached to an oligomeric or polymeric framework (*e.g.*, polylysine, dextran, hydroxyethyl starch and the like) are within the scope of the present invention. The framework is preferably polyfunctional (*i.e.* having an array of reactive sites for attaching compounds of the invention). Moreover, the framework can be derivatized with a single species of the invention or more than one species of the invention.


Moreover, the present invention includes compounds within the motif set forth in Formula I, which are functionalized to afford compounds having water-solubility that is enhanced relative to analogous compounds that are not similarly functionalized. Thus, any of the substituents set forth herein can be replaced with analogous radicals that have enhanced water solubility. For example, it is within the scope of the invention to, for example, replace a hydroxyl group with a diol, or an amine with a quaternary amine, hydroxy amine or similar more water-soluble moiety. In a preferred embodiment, additional water solubility is imparted by substitution at a site not essential for the ion channel activity of the compounds set forth herein with a moiety that enhances the water solubility of the parent compounds. Methods of enhancing the water-solubility of organic compounds are known in the art. Such methods include, but are not limited to, functionalizing an organic nucleus with a permanently charged moiety, *e.g.*, quaternary ammonium, or a group that is charged at a physiologically relevant pH, *e.g.* carboxylic acid, amine. Other methods include, appending to the organic nucleus hydroxyl- or amine-containing groups, *e.g.* alcohols, polyols, polyethers, and the like. Representative examples include, but are not limited to, polylysine, polyethyleneimine, poly(ethyleneglycol) and poly(propyleneglycol). Suitable functionalization chemistries and strategies for these compounds are known in the art. *See*, for example, Dunn, R.L., *et al.*, Eds. POLYMERIC DRUGS AND DRUG DELIVERY SYSTEMS, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991.

Preparation of Sodium Channel Inhibitors

Compounds of the present invention may be prepared using starting materials readily available from commercial suppliers or known intermediates. Examples of starting materials available from commercial suppliers include, but are not limited to,

5 3-methyl-2-phenylpyrazole-4-carboxylic acid, 1-phenyl-5-propyl-1H-pyrazole-4-carboxylic acid, 1-4-chlorophenyl-5-propyl-1H-pyrazole-4-carboxylic acid, 2-(4-chlorophenyl)-3-trifluoromethylpyrazole-4-carboxylic acid, 1-4-(4-chlorophenyl)-1,3-thiazole-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid, 5-fluoro-1-phenylpyrazole-4-carboxylic acid and

10 1-(4-fluorophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid. Scheme 1 sets forth an exemplary synthetic scheme for the preparation of known intermediates used to prepare compounds of the invention.



Scheme 1


In Scheme 1, anhydride **a** is contacted with allyl ether **b** to form adduct **c**. The pyrazole ring system **d** is formed by contacting adduct **c** with hydrazine or a hydrazine derivative. The trifluoromethyl group of the pyrazole ketone **d** is removed by treatment with base to afford the carboxylic acid **e**.

20 Numerous routes are available for elaborating the carboxylic acid moiety of intermediates of the invention. In an exemplary procedure, the pyrazole carboxylic acid (compound **f**; Scheme 2) is activated via conversion to the carboxylic acid chloride (compound **g**; Scheme 2) and made to react with an amine (e.g.; HNR^4R^5) in an organic solvent such as dichloromethane or tetrahydrofuran in the presence of a base such as triethylamine or pyridine to give an amide of Formula I where Y is:

25




and X is O (compound h; Scheme 2). One skilled in the art will recognize that an amide of the invention may be converted to a thioamido (i.e.; X is S) by treatment with Lawesson's reagent or other methods known in the literature.



Scheme 2

Compounds of the present invention may also be prepared as shown in Schemes 3-6. In Scheme 3, the pyrazole amine (compound i) is made to react with a
10 carboxylic acid chloride (e.g.; R^7COCl) using similar conditions described above to give

the amide of formula I where Y is R^6 , R^6 is H and Z is O.




Scheme 3

15


In Scheme 4, the pyrazole amine (i) may be made to react with an isocyanate in an organic solvent such as dichloromethane or tetrahydrofuran to give the

urea (compound k) where Y is R^6 , R^6 is H, Z is O and R^7 is amino. Alternatively, the pyrazole amine (compound i) may be made to react with an isothiocyanate to give a
20 thiourea (i.e.; Z is S).



Scheme 4

In Scheme 5, the pyrazole amine (i) may be made to react with the
 5 oxazolidinone intermediate (compound I) in an organic solvent such as tetrahydrofuran, acetonitrile or n-butanol, typically at elevated temperature (50-100°C), to give the sulfenyl urea. Methods used to prepare oxazolidinone are described in the literature.




Scheme 5

10

In Scheme 6, the pyrazole amine may be made to react with the phenoxy
 intermediate in an organic solvent such as tetrahydrofuran, acetonitrile or n-butanol,
 typically at elevated temperature (50-100°C), to give the cyanoguanidine. Methods used
 to prepare the phenoxy intermediate are described in the literature.

15



Scheme 6

II. ASSAYS FOR BLOCKERS OF SODIUM ION CHANNELS

20

PN3 monomers as well as PN3 alleles and polymorphic variants are
 subunits of sodium channels. The activity of a sodium channel comprising PN3 subunits
 can be assessed using a variety of *in vitro* and *in vivo* assays, *e.g.*, measuring current,
 measuring membrane potential, measuring ion flux, *e.g.*, sodium or guanidinium,
 measuring sodium concentration, measuring second messengers and transcription levels,
 25 and using *e.g.*, voltage-sensitive dyes, radioactive tracers, and patch-clamp
 electrophysiology.

A number of experimental models in the rat are appropriate for assessing the efficacy of the compounds of the invention. For example, the tight ligation of spinal nerves described by Kim *et al.*, *Pain* 50: 355-363 (1992) can be used to experimentally determine the effect of the compounds of the invention on a PN3 channel. For example, a sodium channel blockade *in vitro* assay can be used to determine the effectiveness of compounds of Formula I as sodium channel blockers in an *in vitro* model by the inhibition of compound action potential propagation in isolated nerve preparations (Kourtney and Stricharz, LOCAL ANESTHETICS, Springer-Verlag, New York, 1987). The mechanical allodynia *in vivo* assay is also of use in determining the efficacy of compounds of the invention (Kim and Chung *Pain* 50:355 (1992)). Mechanical sensitivity can be assessed using a procedure described by Chaplan *et al.*, *J. Neurosci. Methods* 53: 55-63 (1994). Other assays of use are known to those of skill in the art. See, for example, Loughhead *et al.*, U.S. Patent No. 6,262,078.

Inhibitors of the PN3 sodium channels can be tested using biologically active recombinant PN3, or naturally occurring TTX-resistant sodium channels, or by using native cells, like cells from the nervous system expressing a PN3 channel. PN3 channels can be isolated, co-expressed or expressed in a cell, or expressed in a membrane derived from a cell. In such assays, PN3 is expressed alone to form a homomeric sodium channel or is co-expressed with a second subunit (*e.g.*, another PN3 family member) so as to form a heteromeric sodium channel. Exemplary expression vectors include, but are not limited to, PN3-pCDNA3.1. The PN3 channel is stably expressed in mammalian expression systems.

Inhibition can be tested using one of the *in vitro* or *in vivo* assays described above. Samples or assays that are treated with a potential sodium channel inhibitor or activator are compared to control samples without the test compound, to examine the extent of inhibition. Control samples (untreated with activators or inhibitors) are assigned a relative sodium channel activity value of 100. Inhibition of channels comprising PN3 is achieved when the sodium channel activity value relative to the control is less than 70%, preferably less than 40% and still more preferably, less than 30%. Compounds that decrease the flux of ions will cause a detectable decrease in the ion current density by decreasing the probability of a channel comprising PN3 being open, by decreasing conductance through the channel, decreasing the number of channels, or decreasing the expression of channels.

Changes in ion flux may be assessed by determining changes in polarization (*i.e.*, electrical potential) of the cell or membrane expressing the sodium channel. A preferred means to determine changes in cellular polarization is by measuring changes in current or voltage with the voltage-clamp and patch-clamp techniques, using the “cell-attached” mode, the “inside-out” mode, the “outside-out” mode, the “perforated cell” mode, the “one or two electrode” mode, or the “whole cell” mode (*see, e.g.*, Ackerman *et al.*, *New Engl. J. Med.* 336: 1575-1595 (1997)). Whole cell currents are conveniently determined using the standard methodology (*see, e.g.*, Hamil *et al.*, *Pflugers. Archiv.* 391: 85 (1981)). Other known assays include: radiolabeled rubidium flux assays and fluorescence assays using voltage-sensitive dyes (*see, e.g.*, Vestergaard-Bogind *et al.*, *J. Membrane Biol.* 88: 67-75 (1988); Daniel *et al.*, *J. Pharmacol. Meth.* 25: 185-193 (1991); Holevinsky *et al.*, *J. Membrane Biology* 137: 59-70 (1994)). Assays for compounds capable of inhibiting or increasing sodium flux through the channel proteins can be performed by application of the compounds to a bath solution in contact with and comprising cells having a channel of the present invention (*see, e.g.*, Blatz *et al.*, *Nature* 323: 718-720 (1986); Park, *J. Physiol.* 481: 555-570 (1994)). Generally, the compounds to be tested are present in the range from about 1 pM to about 100 mM, preferably from about 1 pM to about 1 μ M.

The effects of the test compounds upon the function of the channels can be measured by changes in the electrical currents or ionic flux or by the consequences of changes in currents and flux. Changes in electrical current or ionic flux are measured by either increases or decreases in flux of ions such as sodium or guanidinium ions (*see, e.g.*, Berger *et al.*, U.S. Patent No. 5,688,830). The cations can be measured in a variety of standard ways. They can be measured directly by concentration changes of the ions or indirectly by membrane potential or by radio-labeling of the ions. Consequences of the test compound on ion flux can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test compound on the channels of this invention. The effects of a test compound can be measured by a toxin-binding assay. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers, changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as Ca^{2+} , or cyclic nucleotides.

High throughput screening (HTS) is of use in identifying promising candidates of the invention. Physiologically, Na channels open and close on a ms timescale. To overcome the short time in which channels are open the HTS assay can be run in the presence of an agent that modifies the gating of the channel, such as
5 deltamethrin. This agent modifies the gating of Na channels and keeps the pore open for extended periods of time. In addition, while Na channels are primarily selective for Na, other monovalent cations can permeate the channel.

The specificity and effect of the PN3 blocking agents of the invention can also be assayed against non-specific blockers of PN3, such as tetracaine, mexilitine, and
10 flecainide.

III. PHARMACEUTICAL COMPOSITIONS OF SODIUM CHANNEL OPENERS

In another aspect, the present invention provides pharmaceutical
15 compositions comprising a pharmaceutically acceptable excipient and a pyrazole, such as a compound according to Formula I.

Formulation of the Compounds (Compositions)

The compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms. Thus, the compounds of
20 the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. Accordingly, the present invention also provides pharmaceutical
25 compositions comprising a pharmaceutically acceptable carrier or excipient and a neutral compound of the invention or a pharmaceutically acceptable salt thereof.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and
30 dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

5 The powders and tablets preferably contain from 5% or 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with
10 encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty
15 acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid
20 preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as
25 natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may
30 contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package

containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

10 IV. METHODS FOR INHIBITING ION FLOW IN VOLTAGE-DEPENDENT SODIUM CHANNELS

In yet another aspect, the present invention provides methods for decreasing ion flow through voltage dependent sodium channels in a cell, comprising contacting a cell containing the target ion channels with a sodium channel-inhibiting amount of a pyrazole, such as a compound of Formula I.

The methods provided in this aspect of the invention are useful for the diagnosis of conditions that can be treated by inhibiting ion flux through voltage-dependent sodium channels, or for determining if a patient will be responsive to therapeutic agents, which act by inhibiting sodium channels.

20

V. METHODS FOR TREATING CONDITIONS MEDIATED BY VOLTAGE-DEPENDENT SODIUM CHANNELS

In still another aspect, the present invention provides a method for the treatment of a disorder or condition through inhibition of a voltage-dependent sodium channel. In this method, a subject in need of such treatment is administered an effective amount of a pyrazole compound, such as a compound according to Formula I. In a preferred embodiment, the compounds provided herein are used to treat a disorder or condition by inhibiting an ion channel of the voltage gated sodium channel family, *e.g.*, PN3.

30

The compounds provided herein are useful as sodium channel inhibitors and find therapeutic utility via inhibition of voltage-dependent sodium channels in the treatment of diseases or conditions. The sodium channels that are typically inhibited are described herein as voltage-dependent sodium channels such as the PN3 sodium channels.

The compounds of the invention are particularly preferred for use in the treating, preventing or ameliorating pain or seizures. The method includes administering to a patient in need of such treatment, a therapeutically effective amount of a pyrazole compound, e.g., a compound of the invention or a pharmaceutically acceptable salt thereof.

The compounds, compositions and methods of the present invention are of particular use in treating pain, including both inflammatory and neuropathic pain. Exemplary forms of pain treated by a compound of the invention include, postoperative pain, osteoarthritis pain, pain associated with metastatic cancer, neuropathy secondary to metastatic inflammation, trigeminal neuralgia, glossopharyngeal neuralgia, adipositis dolorosa, burn pain, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, pain following stroke, thalamic lesions, radiculopathy, and other forms of neuralgic, neuropathic, and idiopathic pain syndromes.

Idiopathic pain is pain of unknown origin, for example, phantom limb pain. Neuropathic pain is generally caused by injury or infection of the peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies.

Moreover, any sodium channel inhibitory substance possessed of satisfactory sodium channel inhibiting activity coupled with favorable intracranial transfer kinetics and metabolic stability is expected to show good efficacy in central nervous system (CNS) diseases and disorders such as central nervous system ischemia, central nervous system trauma (*e.g.* brain trauma, spinal cord injury, whiplash injury, *etc.*), epilepsy, seizures, neurodegenerative diseases (*e.g.* amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington's chorea, Parkinson's disease, diabetic neuropathy, *etc.*), vascular dementia (*e.g.* multi-infarct dementia, Binswanger's disease, *etc.*), manic-depressive psychosis, depression, schizophrenia, chronic pain, trigeminal neuralgia, migraine, ataxia, bipolar disorder, spasticity, mood disorders, psychotic disorders, hearing and vision loss, age-related memory loss, learning deficiencies, anxiety and cerebral edema.

In treatment of the above conditions, the compounds utilized in the method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily. A daily dose range of about 0.1 mg/kg to about 100 mg/kg is more typical. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed.

Determination of the proper dosage for a particular situation is within the skill of the practitioner: Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.


EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

In the examples below, unless otherwise stated, temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature (typically a range of from about 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mmHg) with a bath temperature of up to 60°C; the course of reactions was typically followed by thin layer chromatography and reaction times are provided for illustration only; products exhibited satisfactory ¹H-NMR and/or LCMS data; yields (when provided) are for illustration only; and the following conventional abbreviations are also used: mp (melting point), L (liter), mL (milliliters), mmol (millimoles), g (grams), mg (milligrams), min (minutes), LCMS (liquid chromatography-mass spectrometry) and h (hours), PS (polystyrene), DIEA (diisopropylethylamine).

EXAMPLE 1

Preparation of 1-(3-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid




5 1,1,1,5,5,5-Hexafluoro-3-isobutoxymethylen-pentane-2,4-dione was prepared according to experimental procedures described in *Synthesis* 1990, 347-350.

3-Chlorophenylhydrazine (1.04 g, 7.29 mmol) was added to a solution of 1,1,1,5,5,5-hexafluoro-3-isobutoxymethylen-pentane-2,4-dione (2.13 g, 7.29 mmol) in acetonitrile (3 mL) at 0 °C. The reaction mixture was warmed to room temperature, stirred for 16 h and concentrated under reduced pressure. The crude residue was treated with methanol (25 mL) and potassium hydroxide (2.00 g) and the reaction mixture refluxed for 18 h. The reaction mixture was concentrated under reduced pressure and the crude product was taken up in water, acidified with 6M hydrochloric acid and extracted with ethyl acetate (5 x 50 mL). The organic layers were collected, concentrated and crude product purified by column chromatography on silica gel to give 1-(3-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid. LCMS $m/z = 288.9(M-H)^-$.

EXAMPLE 2

Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid-pyridine-4-ylamide




20 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.100 g, 0.324 mmol) was added to a solution of 4-aminopyridine (0.036 g, 0.387 mmol) and pyridine (0.078 mL, 0.969 mmol) in acetonitrile (10 mL). The reaction mixture was heated at 60 °C for 12 h, concentrated and the crude product was purified by column

chromatography on silica gel to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridine-4-ylamide. LCMS $m/z = 366.9$ (M+H)⁺.

EXAMPLE 3


5 *Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methane sulfonyl-phenyl)-amide*



1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.250 g, 0.808 mmol) was added to a solution of 3-methylsulfonylaniline hydrochloride (0.184 g, 0.889 mmol) and triethylamine (0.563 mL, 4.04 mmol) in acetonitrile (20 mL). The reaction mixture heated at 60 °C for 12 h, concentrated and crude product purified by column chromatography on silica gel to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methane sulfonyl-phenyl)-amide. ¹H-NMR (CD₃OD, 300 MHz) δ 8.37 (s, 1H), 8.17 (s, 1H), 7.97 (d, 1H, J = 8.5 Hz), 7.73 (d, 1H, J = 8.0 Hz), 7.59-7.66 (m, 3H), 7.51 (d, 2H, J = 8.8 Hz), 3.15 (s, 3H); LCMS $m/z = 443.9$ (M+H)⁺.

EXAMPLE 4

Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide




1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.100 g, 0.324 mmol) was added to a solution of 2-(3-fluoro-phenyl) ethylamine (0.051 mL, 0.389 mmol) and triethylamine (0.135 mL, 0.972 mmol) in acetonitrile (10 mL). The reaction mixture stirred for 1 hr at room temperature, concentrated and crude product purified by column chromatography on silica gel to give 1-(4-chloro-phenyl)-5-

trifluoromethyl-1*H*-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide. LCMS $m/z = 412.0$ ($M+H$)⁺.

EXAMPLE 5

- 5 *Preparation of 1-(3-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide*)




Benzotriazole-1-yloxytris(dimethylamino)phosphonium

- hexafluorophosphate (BOP) (0.083 g; 0.189 mmol) was added to a solution of 1-(3-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carboxylic acid (0.050 g; 0.172 mmol), 3-trifluoromethyl benzylamine (0.030 g; 0.206 mmol) and triethylamine (0.072 mL; 0.516 mmol) in tetrahydrofuran (10 mL). The reaction mixture was stirred at room temperature for 4 h, concentrated and the crude product purified by column chromatography on silica gel to give 1-(3-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide. LCMS $m/z = 448.8$ ($M+H$)⁺.

EXAMPLE 6

- Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carboxylic acid (2,4-difluoro-phenyl)-amide*



20


- 2,4-difluoro-phenylamine (0.004 g; 0.029 mmol) was added to a suspension of 1-(4-chloro-phenyl)-5-trifluoromethyl-1*H*-pyrazole-4-carboxylic acid (0.010 g; 0.032 mmol) and PS-DIEA (0.1 g) in acetonitrile (2 mL). The reaction mixture was shaken at room temperature for 12 h at which time PS-trisamine (0.1 g) was added to remove the excess acid chloride. After an additional 12 h of shaking, the reaction mixture was filtered and

25

concentrated to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-difluoro-phenyl)-amide. LCMS $m/z = 399.8$ (M-H)⁻.

EXAMPLE 7


5 *Preparation of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl)-amide*




2-Fluoro-3-trifluoromethyl-phenylamine (0.007 g; 0.039 mmol) was added to a suspension of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (0.010 g; 0.032 mmol) and PS-DIEA (0.1g) in acetonitrile (2 mL). The reaction mixture was shaken at room temperature for 12 h at which time PS-TSCl (0.2 g) high loading was added to remove the excess amine. After an additional 12 h of shaking, the reaction mixture was filtered and concentrated to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl)-amide. LCMS $m/z =$
15 449.9 (M-H)⁻.

EXAMPLE 8

Preparation of 1-(4-fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide




20 3-Trifluoromethyl benzylamine (0.014 mL, 0.100 mmole) was added to a suspension of 1-(4-fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (0.030 g; 0.109 mmol) and PS-Carbodiimide (0.2 g) in methylene chloride (2 mL). The reaction mixture was shaken at room temperature for 12 h at which time the reaction
25 mixture was filtered and concentrated to give 1-(4-fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide. LCMS $m/z = 432.3$ (M+H)⁺.

EXAMPLE 9*Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine*


Bromine (4.70 mL, 100 mmol) was added to a solution of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide (1.20 g, 4.15 mmol) in 3M NaOH (100 mL). The reaction mixture was heated at 100 °C for 1 hour, cooled to room temperature and extracted with EtOAc (3 x 50 mL). Organic layers were collected, concentrated and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine (0.408 g, 38 %).

10

EXAMPLE 10*Preparation of 1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-methanesulfonyl-phenyl)-urea*

Triphosgene (0.042 g, 0.140 mmol) was added to a solution of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine (0.100 g, 0.382 mmol) and Na₂CO₃ (0.405 g, 3.82 mmol) in CH₂Cl₂/H₂O (50 mL, 1:1) and stirred at room temperature for 30 min. 3-Methanesulfonyl-phenylamine HCl (0.095 g, 0.458 mmol) was added to the reaction mixture, stirred at room temperature for 2 hrs, organic layer collected and aqueous layer extracted with EtOAc (3 x 25 mL). Organic layers were collected, concentrated and crude product purified by column chromatography to give 1-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-methanesulfonyl-phenyl)-urea (0.040 g, 22 %).


25

EXAMPLE 11

Excess 3,4-dichlorophenylisocyanate was added to a solution of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-ylamine (13.1 mg, 0.05 mmol) in THF (1 mL). The reaction was shaken overnight then the excess 3,4-dichlorophenylisocyanate was scavenged with PS-trisamine. The product (21.4 mg, 95%) was isolated by filtration and evaporation.

EXAMPLE 12


Preparation of 3-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonyl fluoride



1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl chloride (3.00 g, 9.70 mmol) was added to 3-amino-benzenesulfonyl fluoride (1.87 g, 10.6 mmol) in CH_2Cl_2 (50 ml) containing pyridine (2.35 ml, 29.1 mmol). Reaction mixture stirred overnight at room temperature, concentrated under reduced pressure and crude product purified by column chromatography to give 3-[[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonyl fluoride (3.23 g, 74 %).

EXAMPLE 13


Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyclopropylsulfamoyl-phenyl)-amide



Cyclopropyl amine (0.012 mL, 0.167 mmol) was added to 3-[[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonyl fluoride (0.025 g, 0.055 mmol) in CH_2Cl_2 (10 ml). Reaction mixture stirred overnight at room temperature, concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyclopropylsulfamoyl-phenyl)-amide (0.015 g, 55 %).

EXAMPLE 14


Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- cyano-2-phenyl-isourea)-amide



5 Diphenyl N-cyanocarbonimidate (0.235 g, 0.984 mmol) was added to 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.250 g, 0.656 mmol) in CH₃CN (10 mL) and heated at 80 °C overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- cyano-2-phenyl-isourea)-amide (0.258 g, 75 %).

EXAMPLE 15


Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid N'-methyl-cyanoguanidine



15 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- cyano-2-phenyl-isourea)-amide (0.050 g, 0.095 mmol) was added to a solution of methylamine (10 mL, 20 mmol, 2M in THF) and stirred overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid N'-methyl-cyanoguanidine (0.038 g, 88 %).

EXAMPLE 16


Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3- methylsulfone-2-phenyl-isourea)-amide.



Diphenyl N-methylsulfone-carbonimidate (0.573 g, 1.97 mmol) was added to 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.500 g, 1.31 mmol) in CH₃CN (20 mL) and heated at 80 °C for 2 days. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methylsulfone-2-phenyl-isourea)-amide (0.700 g, 92 %).

EXAMPLE 17


Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(N'-methylsulfone-N''-cyclopropyl-guanidino)-phenyl]-amide



1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methylsulfone-2-phenyl-isourea)-amide (0.025 g, 0.0432 mmol) was added to a solution of cyclopropyl amine (0.030 mL, 0.432 mmol) in THF (5 mL) and stirred overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(N'-methylsulfone-N''-cyclopropyl-guanidino)-phenyl]-amide (0.015 g, 65 %).

EXAMPLE 18

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide.




1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide (0.100 g, 0.323 mmol) was added to 3-amino-boronic acid monohydrate (0.060 g, 0.388 mmol) in CH₂Cl₂ (5 ml) containing pyridine (0.078 ml, 0.970 mmol). Reaction mixture stirred 2 hours at 80 °C, concentrated under reduced pressure and crude product purified

by column chromatography to give 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide. (0.130 g, 98 %).

EXAMPLE 19


5 *Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-thiazol-2-yl-phenyl)-amide*



Dichlorobis(triphenylphosphine)palladium (II) (0.002 g, 0.00244 mmol) was added to a degassed (N₂) mixture of 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-boronic acid-phenyl)-amide (0.100 g, 0.244 mmol), Na₂CO₃ (0.052 g, 0.488 mmol), and 2-Bromo-thiazole (0.048 g, 0.292 mmol) in H₂O/toluene (1 mL/2 mL). Reaction mixture heated at 80 °C for 12 hours, cooled to room temperature and extracted with EtOAc (3 x 5 mL). Organic layers were collected, concentrated and crude product purified by column chromatography to give 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-thiazol-2-yl-phenyl)-amide (0.074 g, 67 %).

EXAMPLE 20


20 *Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamide-phenyl)-amide.*



Sulfamide (0.010 g, 0.105 mmol) was added to 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.020 g, 0.00525 mmol) in 1,4-dioxane (2 mL) and heated at 120 °C overnight. Reaction mixture concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamide-phenyl)-amide (0.013 g, 54 %).

EXAMPLE 21

Preparation of 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-dimethylsulfamide-phenyl)-amide.



5 Dimethylsulfamoyl chloride (0.010 g, 0.105 mmol) was added to 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide (0.025 g, 0.0656 mmol) in CH₃CN (2 mL) containing pyridine (0.016 mL, 0.196 mmol). Reaction mixture stirred overnight, concentrated under reduced pressure and crude product purified by column chromatography to give 1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-dimethylsulfamide-phenyl)-amide
10 (0.019 g, 59 %).

EXAMPLE 22

¹⁴C Guanidinium Ion Influx Binding Assay

15 PN3 stably expressed in a host cell line were maintained in DMEM with 5% fetal bovine serum and 300 µg/ml G-418. The cells were subcultured and grown to confluence in 96-well plates 24-48 h before each experiment. After the growth medium was removed, the cells were washed with warm buffer (25 mM Hepes-Tris, 135 mM choline chloride, 5.4 mM potassium chloride, 0.98 mM magnesium sulfate, 5.5 mM
20 glucose, and 1 mg/ml BSA, pH 7.4) and incubated in buffer on a 36 °C slide warmer for approximately 10 minutes. Various concentrations of the test compounds or standard sodium channel blockers (10 µM) and then deltamethrine (10 µM) were added to each well. After the cells were exposed to deltamethrine for 5 minutes, 5 µM of ¹⁴C-guanidinium was added, incubated with the radioligand (30-60 min), washed with ice-cold
25 buffer, and dissolved in 0.1N sodium hydroxide. The radioactivity and the protein concentration of each cell lysate were determined by liquid scintillation counting and the protein assay using Pierce BCA reagent.

EXAMPLE 23

23.1 Mechanical Allodynia *In vivo* Assay

This assay determines the effectiveness of compounds of Formula I in relieving one of the symptoms in an *in vivo* model of neuropathic pain produced by spinal nerve ligation, namely mechanical allodynia.

Tactile allodynia was induced in rats using the procedures described by Kim and Chung, *Pain* 50: 355-363 (1992). Briefly, the rats were anesthetized with 2-5% inhaled isoflurane and maintained by 1% isoflurane. Each animal was then placed in a prone position, a 3 cm lateral incision was made, and the left paraspinal muscles separated from the spinous process at the L₄-S₂ level. The L₆ transverse process was then removed in order to visually identify the L₄-L₆ spinal nerves. The L₅ and L₆ spinal nerves were then individually isolated and tightly ligated with silk thread. The wound was then closed in layers by silk sutures. These procedures produced rats which developed a significant increase in sensitivity to mechanical stimuli that did not elicit a response in normal rats.

Mechanical sensitivity was assessed using a procedure described by Chaplan *et al.*, *J. Neurosci. Methods* 53: 55-63 (1994). Briefly, a series of eight Von Frey filaments of varying rigidity strength were applied to the plantar surface of the hind paw ipsilateral to the ligations with just enough force to bend the filament. The filaments were held in this position for no more than three seconds or until a positive allodynic response was displayed by the rat. A positive allodynic response consisted of lifting the affected paw followed immediately by licking or shaking of the paw. The order and frequency with which the individual filaments were applied were determined by using Dixon up-down method. Testing was initiated with the middle hair of the series with subsequent filaments being applied in consecutive fashion, either ascending or descending, depending on whether a negative or positive response, respectively, was obtained with the initial filament.

23.2 Thermal Hyperalgesia *In vivo* Assay

This assay determines the effectiveness of compounds in relieving one of the symptoms of neuropathic pain produced by unilateral mononeuropathy, namely thermal hyperalgesia.

The rats having had surgery as described above were assessed for thermal hyperalgesia sensitivity at least 5-7 days post-surgery. Briefly, the rats were placed

beneath inverted plexiglass cages upon an elevated glass platform and a radiant heat source beneath the glass was aimed at the plantar hindpaw. The duration of time before the hindpaw was withdrawn from the floor was measured to the nearest tenth of a second. The cutoff time for the heat stimulus was 40 seconds, and the light was calibrated such that this stimulus duration did not burn or blister the skin. Three latency measurements were taken for each hindpaw ipsilateral to the ligation in each test session, alternating left and right hindpaws, with greater than 1 minute intervals between tests.

23.3 Results

The results show that after oral administration the compounds of the invention produce efficacious anti-allodynic effects at doses less than or equal to 100 mg/kg. The results show that after IV administration the compounds of the invention produce efficacious anti-hyperalgesic effects at doses less than or equal to 30 mg/kg. Overall, the compounds of the present invention were found to be effective in reversing mechanical allodynia-like and thermal hyperalgesia-like symptoms.

EXAMPLE 24

Example 24 sets forth representative compounds of the invention.

compound #	name	MZ
1	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	423
2	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-2-ylmethyl)-amide	380
3	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	380
4	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-4-ylmethyl)-amide	380
5	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4,6-trichloro-phenyl)-amide	467
6	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	447

7	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide	429
8	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	461
9	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amide	467
10	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	455
11	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-methyl-isoxazol-3-yl)-amide	370
12	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-pyrazol-3-yl)-amide	355
13	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-2H-pyrazol-3-yl)-amide	380
14	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-ethyl-2H-pyrazol-3-yl)-amide	383
15	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-hydroxy-1H-pyrazol-3-yl)-amide	371
16	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isoxazol-3-ylamide	356
17	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-phenyl-2H-pyrazol-3-yl)-amide	431
18	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,5-dimethyl-2H-pyrazol-3-yl)-amide	383
19	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-bromo-5-methyl-isoxazol-3-yl)-amide	448
20	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	445

21	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-amide	447
22	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-3-ylamide	366
23	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	366
24	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	447
25	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	447
26	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-4-fluoro-phenyl)-4-cyano-2H-pyrazol-3-yl]-amide	508
27	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-bromo-6-methyl-pyridin-2-yl)-amide	458
28	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	453
29	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	393
30	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,6-dimethoxy-benzylamide	439
31	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 2,6-dimethoxy-benzylamide	379
32	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	432
33	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	372
34	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-propionic acid methyl ester	375
35	2-[(1-Phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid methyl ester	315

36	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino]-propionic acid methyl ester	417
37	4-Methyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-pentanoic acid methyl ester	357
38	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino]-3-phenyl-propionic acid methyl ester	451
39	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid methyl ester	391
40	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-5-trifluoromethyl-phenyl)-amide	451
41	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-fluoro-5-trifluoromethyl-phenyl)-amide	391
42	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino]-3-(1H-indol-3-yl)-propionic acid methyl ester	490
43	3-(1H-Indol-3-yl)-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid methyl ester	430
44	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	453
45	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	393
46	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	399
47	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	339
48	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (furan-2-ylmethyl)-amide	369
49	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (furan-2-ylmethyl)-amide	309
50	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyridin-2-yl-ethyl)-amide	394
51	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-pyridin-2-yl-ethyl)-amide	334

52	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	448
53	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	388
54	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide	385
55	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide	325
56	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide	419
57	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-ylmethyl)-amide	359
58	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	400
59	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	340
60	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyridin-3-yl-ethyl)-amide	394
61	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-pyridin-3-yl-ethyl)-amide	334
62	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-phenoxy-ethyl)-amide	409
63	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-phenoxy-ethyl)-amide	349
64	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide	414
65	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide	354
66	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	395
67	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	515

68	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	455
69	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-nitro-benzylamide	424
70	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 4-nitro-benzylamide	364
71	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-imidazol-1-yl-propyl)-amide	397
72	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-imidazol-1-yl-propyl)-amide	337
73	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	373
74	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	313
75	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	385
76	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	325
77	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isobutyl-amide	345
78	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid isobutyl-amide	285
79	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid indan-1-ylamide	405
80	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid indan-1-ylamide	345
81	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	357
82	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	297
83	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-morpholin-4-yl-ethyl)-amide	402

84	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-morpholin-4-yl-ethyl)-amide	342
85	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-dimethoxy-benzylamide	439
86	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 3,5-dimethoxy-benzylamide	379
87	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	363
88	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	387
89	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-dimethylamino-ethyl)-amide	360
90	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-dimethylamino-ethyl)-amide	300
91	{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-methyl-amino}-acetic acid ethyl ester	389
92	[Methyl-(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-acetic acid ethyl ester	329
93	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-pyrrolidin-1-yl-methanone	343
94	(1-Phenyl-5-propyl-1H-pyrazol-4-yl)-pyrrolidin-1-yl-methanone	283
95	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone	405
96	(3,4-Dihydro-1H-isoquinolin-2-yl)-(1-phenyl-5-propyl-1H-pyrazol-4-yl)-methanone	345
97	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzyl-ethyl-amide	407
98	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid benzyl-ethyl-amide	347
99	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-thiomorpholin-4-yl-methanone	375

100	(1-Phenyl-5-propyl-1H-pyrazol-4-yl)-thiomorpholin-4-yl-methanone	315
101	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-pyrrolidine-2-carboxylic acid dimethylamide	414
102	1-(1-Phenyl-5-propyl-1H-pyrazole-4-carbonyl)-pyrrolidine-2-carboxylic acid dimethylamide	354
103	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methoxy-benzyl)-(2-pyridin-2-yl-ethyl)-amide	514
104	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,4-dichloro-benzyl)-(2-pyridin-2-yl-ethyl)-amide	552
105	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-benzyl)-(2-pyridin-2-yl-ethyl)-amide	502
106	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-methyl-benzyl)-(2-pyridin-2-yl-ethyl)-amide	498
107	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,4-dichloro-benzyl)-(2-pyridin-3-yl-ethyl)-amide	552
108	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,4-dimethoxy-benzyl)-(1-phenyl-ethyl)-amide	543
109	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyano-ethyl)-phenethyl-amide	446
110	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,4-dichloro-benzyl)-(2-pyridin-4-yl-ethyl)-amide	552
111	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-benzooxazol-2-yl)-amide	440
112	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,5-dichloro-pyridin-2-yl)-amide	434

113	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	400
114	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	393
115	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyridin-4-yl-ethyl)-amide	394
116	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-chloro-5-trifluoromethyl-pyridin-2-yl)-amide	468
117	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-diethylcarbamoyl-phenyl)-amide	464
118	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenyl]-amide	525
119	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	399
120	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-2-methyl-1H-benzoimidazol-5-yl)-amide	447
121	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(6-methyl-benzothiazol-2-yl)-phenyl]-amide	512
122	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methoxy-biphenyl-4-yl)-amide	471
123	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-indazol-6-yl)-amide	405
124	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenylamide	365
125	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-diethylcarbamoyl-phenyl)-amide	404
126	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenyl]-amide	465

127	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	339
128	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1-ethyl-2-methyl-1H-benzoimidazol-5-yl)-amide	387
129	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [4-(6-methyl-benzothiazol-2-yl)-phenyl]-amide	452
130	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-methoxy-biphenyl-4-yl)-amide	411
131	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1H-indazol-6-yl)-amide	345
132	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid phenylamide	305
133	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-diethylcarbamoyl-phenyl)-amide	430
134	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(5-methyl-isoxazol-3-ylsulfamoyl)-phenyl]-amide	491
135	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	365
136	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-2-methyl-1H-benzoimidazol-5-yl)-amide	413
137	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(6-methyl-benzothiazol-2-yl)-phenyl]-amide	478
138	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methoxy-biphenyl-4-yl)-amide	437
139	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-indazol-6-yl)-amide	371
140	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenylamide	331
141	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid m-tolylamide	379
142	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methoxy-phenyl)-amide	395

143	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	379
144	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzyl-methyl-amide	393
145	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-methoxy-benzylamide	409
146	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-nitro-benzylamide	424
147	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-methyl-benzylamide	393
148	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-3-phenyl-propionic acid benzyl ester	527
149	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-3-phenyl-propionic acid methyl ester	451
150	2-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-3-phenyl-propionic acid tert-butyl ester	493
151	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-amide	429
152	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyano-phenyl)-amide	390
153	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-dimethylamino-benzylamide	422
154	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	443
155	4-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester	437
156	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid benzyl ester	467
157	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid methyl ester	391

158	3-Phenyl-2-[(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid tert-butyl ester	433
159	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-amide	369
160	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-cyano-phenyl)-amide	330
161	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid 4-dimethylamino-benzylamide	362
162	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	383
163	4-[(1-Phenyl-5-propyl-1H-pyrazole-4-carbonyl)-amino]-benzoic acid ethyl ester	377
164	3-Phenyl-2-[(1-phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid benzyl ester	493
165	3-Phenyl-2-[(1-phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid methyl ester	417
166	3-Phenyl-2-[(1-phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-propionic acid tert-butyl ester	459
167	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-amide	395
168	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyano-phenyl)-amide	356
169	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-dimethylamino-benzylamide	388
170	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	409
171	4-[(1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-benzoic acid ethyl ester	403
172	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide	465
173	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	461

174	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl)- methanone	473
175	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-trifluoromethyl-benzyloxy)-amide	463
176	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid benzylamide	291
177	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid tert- butylamide	257
178	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	305
179	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	297
180	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	269
181	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	367
182	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 3,5- bis-trifluoromethyl-benzylamide	427
183	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 3- trifluoromethyl-benzylamide	359
184	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	335
185	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 3,4- dichloro-benzylamide	359
186	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid methyl-(3-trifluoromethyl-benzyl)-amide	461
187	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid ethyl-(3-trifluoromethyl-benzyl)-amide	475
188	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid benzo[1,3]dioxol-5-ylmethyl-methyl- amide	437

189	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzo[1,3]dioxol-5-ylmethyl-ethyl-amide	451
190	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid methyl-thiophen-2-ylmethyl-amide	399
191	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl-thiophen-2-ylmethyl-amide	413
192	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid methyl-(4-trifluoromethyl-benzyl)-amide	461
193	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl-(4-trifluoromethyl-benzyl)-amide	475
194	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzo[1,3]dioxol-5-ylmethyl-(2-dimethylamino-ethyl)-amide	494
195	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-dimethylamino-ethyl)-(3-trifluoromethyl-benzyl)-amide	518
196	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	390
197	1-(6-Ethoxy-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	391
198	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	402
199	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	390
200	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	375
201	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	413
202	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid benzylamide	413
203	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	345

204	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	356
205	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	347
206	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	368
207	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	356
208	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	341
209	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	379
210	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid tert-butylamide	379
211	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	311
212	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	404
213	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	395
214	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	416
215	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	404
216	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	389
217	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	427
218	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid phenethyl-amide	427
219	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	359

220	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	396
221	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	387
222	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	408
223	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	396
224	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	381
225	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	419
226	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	419
227	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	351
228	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	368
229	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	359
230	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	380
231	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	368
232	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	353
233	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	391
234	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid cyclopentylamide	391
235	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	323

236	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	466
237	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	457
238	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	478
239	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	466
240	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	451
241	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	489
242	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	489
243	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	421
244	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	526
245	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	517
246	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	538
247	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	526
248	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	511
249	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	549
250	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	549

251	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	481
252	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	458
253	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H- pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	449
254	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	470
255	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	458
256	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	443
257	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	481
258	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H- pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	481
259	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	413
260	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	434
261	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H- pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5- ylmethyl)-amide	425
262	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	446
263	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	434
264	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	419
265	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	457

266	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	457
267	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	389
268	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	458
269	1-(6-Chloro-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	449
270	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	470
271	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	458
272	1-(4-Methoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	443
273	1-(2,5-Dichloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	481
274	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	481
275	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	413
276	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyrazin-2-ylamide	367
277	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4,6-dichloro-pyrimidin-2-yl)-amide	435
278	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	383
279	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-nitro-phenyl)-amide	410
280	5,6-Dichloro-3-{{1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl}-amino}-pyrazine-2-carboxylic acid methyl ester	493

281	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyclopentyl-ethyl)-amide	385
282	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid benzylamide	243
283	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid tert-butylamide	209
284	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid phenethylamide	257
285	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	249
286	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid cyclopentylamide	221
287	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	319
288	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	379
289	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	311
290	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	287
291	1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	311
292	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-pyrrolidin-1-yl-methanone	327
293	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone	410
294	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-pyridin-2-yl-piperazin-1-yl)-methanone	419
295	(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-[1-(4-fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	476
296	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-methoxy-benzylamide	393

297	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-methoxy-phenoxy)-ethyl]-amide	423
298	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-fluoro-5-trifluoromethyl-benzylamide	449
299	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-methyl-piperazin-1-yl)-methanone	356
300	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	403
301	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [cyclopropyl-(4-methoxy-phenyl)-methyl]-amide	433
302	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,3-dihydro-benzo[d]imidazo[2,1-b]thiazol-6-yl)-amide	447
303	2-{{[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-3-phenyl-propionic acid benzyl ester	511
304	4-{{[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester	421
305	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	427
306	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyclohexyl-1-hydroxymethyl-ethyl)-amide	413
307	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide	369
308	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (furan-2-ylmethyl)-amide	353
309	1-[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-piperidine-3-carboxylic acid amide	384
310	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-phenyl-cyclopropyl)-amide	389

311	[1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- (3-hydroxy-piperidin-1-yl)-methanone	357
312	4-Phenyl-1-(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)- piperidine-4-carbonitrile	398
313	1-(5-tert-Butyl-2-methyl-2H-pyrazole-3-carbonyl)-4- phenyl-piperidine-4-carbonitrile	350
314	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-methanesulfonyl-phenyl)-methyl-amide	457
315	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	461
316	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid methylamide	303
317	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid dimethylamide	317
318	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-acetyl-phenyl)-amide	407
319	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (5-ethanesulfonyl-2-methoxy-phenyl)- amide	487
320	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (4-methanesulfonyl-phenyl)-amide	443
321	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1,1-dioxo-1H-1 λ 6*- benzo[b]thiophen-6-yl)-amide	453
322	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	411
323	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	411
324	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	427
325	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	427

326	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	461
327	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	400
328	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	400
329	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	323
330	(5-Chloro-1-methyl-1H-pyrazol-4-yl)-(4-methyl-piperazin-1-yl)-methanone	242
331	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1-methyl-hexyl)-amide	257
332	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	243
333	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-pyridin-2-yl-ethyl)-amide	264
334	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	427
335	[1-(4-Chloro-phenyl)-5-propyl-1H-pyrazol-4-yl]-(4-methyl-piperazin-1-yl)-methanone	346
336	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-methyl-hexyl)-amide	361
337	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	347
338	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-pyridin-2-yl-ethyl)-amide	368
339	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid ethyl-pyridin-4-ylmethyl-amide	278
340	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid benzyl-isopropyl-amide	291
341	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	332

342	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-diethylamino-propyl)-amide	272
343	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	309
344	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid ethyl-pyridin-4-ylmethyl-amide	382
345	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid benzyl-isopropyl-amide	395
346	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	436
347	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3-diethylamino-propyl)-amide	376
348	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	413
349	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid benzyl-methyl-amide	263
350	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3,4-difluoro-phenyl)-amide	271
351	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethyl-phenyl)-amide	303
352	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid methyl-pyridin-2-yl-amide	250
353	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-phenyl-propyl)-amide	277
354	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid benzyl-methyl-amide	367
355	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3,4-difluoro-phenyl)-amide	375
356	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethyl-phenyl)-amide	407
357	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid methyl-pyridin-2-yl-amide	354

358	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3-phenyl-propyl)-amide	381
359	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-pyridin-4-yl-ethyl)-amide	264
360	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	293
361	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	263
362	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-ethyl-2H-pyrazol-3-yl)-amide	253
363	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	331
364	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-pyridin-4-yl-ethyl)-amide	368
365	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	397
366	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	367
367	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-ethyl-2H-pyrazol-3-yl)-amide	357
368	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	435
369	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	331
370	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	269
371	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	297
372	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	317
373	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	313

374	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	435
375	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	373
376	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	401
377	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	421
378	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	417
379	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	302
380	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	281
381	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	281
382	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	270
383	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	270
384	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	406
385	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	385
386	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	385
387	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	374
388	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	374
389	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid 2,6-dimethoxy-benzylamide	309

390	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	297
391	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	323
392	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	270
393	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (2-phenyl-propyl)-amide	277
394	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid 2,6-dimethoxy-benzylamide	413
395	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	401
396	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	427
397	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	374
398	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-phenyl-propyl)-amide	381
399	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	281
400	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	331
401	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	325
402	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	236
403	5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-benzenesulfonyl-phenyl)-amide	375
404	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	385
405	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	435

406	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (biphenyl-3-ylmethyl)-amide	429
407	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	340
408	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (3-benzenesulfonyl-phenyl)-amide	479
409	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide	425
410	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-hydroxy-phenyl)-amide	381
411	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	411
412	5-Trifluoromethyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	495
413	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-5-methanesulfonyl-phenyl)-amide	461
414	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	427
415	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-hydroxy-phenyl)-ethyl]-amide	409
416	1-(3-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	447
417	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	454
418	1-(4-Amino-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	424
419	1-(2,5-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	393
420	1-(2-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	438

421	1-Benzothiazol-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	450
422	1-(4-Nitro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	438
423	1-(4-Amino-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	408
424	1-(4-Guanidino-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	466
425	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	393
426	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	393
427	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	393
428	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	427
429	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	427
430	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	427
431	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	377
432	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	377
433	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	377
434	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	427
435	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-ethyl-phenyl)-ethyl]-amide	387
436	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	419

437	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	419
438	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-thiophen-2-yl-ethyl)-amide	365
439	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide	363
440	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	379
441	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	379
442	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-methyl-benzylamide	359
443	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-methyl-benzylamide	359
444	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	413
445	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-fluoro-5-trifluoromethyl-benzylamide	431
446	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid [2-(3-hydroxy-phenyl)-ethyl]-amide	409
447	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-hydroxy-phenyl)-ethyl]-amide	375
448	1-(3-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid (3- methanesulfonyl-phenyl)-amide	375
449	1-(3-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3- chloro-phenyl)-ethyl]-amide	359
450	1-(3-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2- (2,6-dichloro-phenyl)-ethyl]-amide	393
451	1-(4-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid (3- methanesulfonyl-phenyl)-amide	375
452	1-(4-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3- chloro-phenyl)-ethyl]-amide	359

453	1-(4-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	393
454	1-Benzyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	355
455	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	339
456	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	373
457	1-p-Tolyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	355
458	1-p-Tolyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	339
459	1-p-Tolyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	373
460	1-(2-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	375
461	1-(2-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	359
462	1-(2-Chloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	393
463	1-(3,4-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	409
464	1-(3,4-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	393
465	1-(3,4-Dichloro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	427
466	1-(4-Bromo-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	419
467	1-(4-Bromo-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	403
468	1-(4-Bromo-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	437

469	1-(4-Fluoro-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	359
470	1-(4-Fluoro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	343
471	1-(4-Fluoro-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	377
472	1-(4-Methoxy-phenyl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	371
473	1-(4-Methoxy-phenyl)-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	355
474	1-(4-Methoxy-phenyl)-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	389
475	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dihydroxy-phenyl)-ethyl]-amide	391
476	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-hydroxy-phenyl)-ethyl]-amide	375
477	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzylamide	363
478	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	377
479	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	411
480	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	411
481	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	411
482	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	445
483	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	445
484	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	445

485	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	395
486	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	395
487	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	395
488	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	445
489	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-phenyl)-amide	433
490	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-difluoro-phenyl)-amide	401
491	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-isopropyl-phenyl)-amide	407
492	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-5-trifluoromethyl-phenyl)-amide	451
493	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropenyl-phenyl)-amide	405
494	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide	393
495	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl)-amide	451
496	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	449
497	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,5-dimethyl-phenyl)-amide	393
498	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,3,4-trifluoro-phenyl)-amide	419
499	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-phenyl)-amide	383
500	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	421

501	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-5-trifluoromethyl-phenyl)-amide	467
502	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethyl-phenyl)-amide	433
503	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid o-tolylamide	379
504	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-dimethyl-phenyl)-amide	393
505	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-tert-butyl-phenyl)-amide	421
506	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,6-dimethyl-phenyl)-amide	393
507	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethoxy-phenyl)-amide	409
508	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-pyridin-3-yl)-amide	400
509	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-dichloro-phenyl)-amide	433
510	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid biphenyl-4-ylamide	441
511	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-2-methyl-phenyl)-amide	413
512	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide	399
513	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide	390
514	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-benzenesulfonyl-phenyl)-amide	
515	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-methoxy-biphenyl-3-yl)-amide	471
516	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-morpholin-4-yl-phenyl)-amide	450

517	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-trifluoromethyl-phenyl)-amide	433
518	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [4-(ethyl-isopropyl-amino)-phenyl]-amide	450
519	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-5-methyl-phenyl)-amide	413
520	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide	448
521	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-dimethylamino-phenyl)-amide	408
522	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-methoxy-2-methyl-phenyl)-amide	409
523	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-methyl-2-oxo-2H-chromen-7-yl)-amide	447
524	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-5-methoxy-phenyl)-amide	429
525	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid quinolin-8-ylamide	416
526	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	430
527	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(1H-indol-2-yl)-phenyl]-amide	480
528	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyanomethyl-phenyl)-amide	404
529	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [5-chloro-2-(4-chloro-phenylsulfanyl)-phenyl]-amide	541
530	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyano-phenyl)-amide	390
531	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-methoxy-phenyl)-methyl-amide	409
532	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-methoxy-phenyl)-amide	395

533	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide	434
534	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-4-trifluoromethyl-phenyl)-amide	467
535	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-fluoro-2-methyl-phenyl)-amide	397
536	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methyl-isothiazol-5-yl)-amide	386
537	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid thiazol-2-ylamide	372
538	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-phenyl-oxazol-2-yl)-amide	432
539	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1,1-dioxo-tetrahydro-1 lambda*6*-thiophen-3-yl)-amide	407
540	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-methylsulfanyl-1H-[1,2,4]triazol-3-yl)-amide	402
541	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-[1,2,4]triazol-3-yl)-amide	356
542	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-trifluoromethyl-[1,3,4]thiadiazol-2-yl)-amide	441
543	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methyl-isoxazol-5-yl)-amide	370
544	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-phenyl-thiazol-2-yl)-amide	448
545	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzothiazol-2-ylamide	422
546	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-amide	405
547	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-methoxy-benzylamide	393

548	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-methoxy-benzylamide	393
549	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-methyl-benzylamide	377
550	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-methyl-benzylamide	377
551	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	397
552	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,4-dichloro-benzylamide	431
553	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	423
554	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,3-dimethoxy-benzylamide	423
555	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	397
556	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyclohexylmethyl-amide	369
557	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dichloro-benzylamide	431
558	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-iodo-benzylamide	489
559	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-benzylamide	381
560	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	431
561	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	357
562	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	407
563	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-5-trifluoromethyl-benzylamide	449

564	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	431
565	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide	499
566	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,6-dimethoxy-benzylamide	423
567	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3,5-dimethoxy-benzylamide	423
568	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-phenyl-ethyl)-amide	377
569	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-2-ylmethyl)-amide	364
570	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	455
571	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	407
572	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide	437
573	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide	437
574	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	391
575	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	405
576	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	405
577	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	405
578	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-hydroxy-phenyl)-ethyl]-amide	393
579	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	383

580	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid o-tolylamide	363
581	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid m-tolylamide	363
582	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methoxy-phenyl)-amide	379
583	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	367
584	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4-difluoro-phenyl)-amide	385
585	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethoxy-phenyl)-amide	449
586	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-phenyl)-amide	399
587	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-phenyl)-amide	407
588	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethyl-phenyl)-amide	373
589	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-pyridin-3-yl)-amide	366
590	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-chloro-pyridin-3-yl)-amide	374
591	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-chloro-pyridin-3-yl)-amide	340
592	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-isopropyl-phenyl)-amide	373
593	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-isopropyl-phenyl)-amide	381
594	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-isopropyl-phenyl)-amide	347
595	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide	365

596	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide	373
597	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide	339
598	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide	359
599	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide	367
600	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethyl-phenyl)-amide	333
601	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide	356
602	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide	364
603	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-cyano-phenyl)-amide	330
604	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	415
605	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	423
606	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	389
607	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-morpholin-4-yl-phenyl)-amide	416
608	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-morpholin-4-yl-phenyl)-amide	424
609	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-morpholin-4-yl-phenyl)-amide	390
610	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-phenyl)-amide	349
611	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-fluoro-phenyl)-amide	357

612	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-fluoro-phenyl)-amide	323
613	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-trifluoromethyl-phenyl)-amide	399
614	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-trifluoromethyl-phenyl)-amide	407
615	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-trifluoromethyl-phenyl)-amide	373
616	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethyl-phenyl)-amide	399
617	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethyl-phenyl)-amide	373
618	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide	414
619	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide	422
620	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide	388
621	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid o-tolylamide	345
622	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid o-tolylamide	353
623	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid o-tolylamide	319
624	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid quinolin-8-ylamide	382
625	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid quinolin-8-ylamide	390
626	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid quinolin-8-ylamide	356
627	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-ethoxy-phenyl)-amide	375

628	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethoxy-phenyl)-amide	383
629	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-ethoxy-phenyl)-amide	349
630	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	437
631	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	445
632	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	411
633	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	387
634	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	395
635	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	361
636	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	367
637	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	389
638	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	397
639	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	363
640	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	351
641	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dichloro-phenyl)-ethyl]-amide	401
642	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	367
643	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	435

644	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	401
645	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	389
646	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	397
647	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	363
648	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	373
649	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	381
650	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	347
651	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-phenoxy-ethyl)-amide	375
652	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (2-phenoxy-ethyl)-amide	383
653	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	387
654	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	395
655	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	361
656	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	385
657	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	393
658	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	359
659	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	387

660	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	395
661	1-Phenyl-5-propyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	361
662	1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid indan-1-ylamide	371
663	1-(4-Chloro-phenyl)-5-propyl-1H-pyrazole-4-carboxylic acid indan-1-ylamide	379
664	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-bromo-phenyl)-ethyl]-amide	471
665	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	423
666	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	407
667	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	421
668	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	421
669	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3,4-dimethyl-phenyl)-ethyl]-amide	421
670	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	423
671	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide	419
672	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4,6-triethyl-phenyl)-amide	449
673	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-ethyl-6-methyl-phenyl)-amide	407
674	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4,6-trimethyl-phenyl)-amide	407
675	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,6-diethyl-phenyl)-amide	421

676	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,5-bis-trifluoromethyl-phenyl)-amide	501
677	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,6-diisopropyl-phenyl)-amide	449
678	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropyl-6-methyl-phenyl)-amide	421
679	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,4,6-triethyl-3-nitro-phenyl)-amide	494
680	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,4-difluoro-phenyl)-amide	401
681	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,5-di-tert-butyl-phenyl)-amide	477
682	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-chloro-2,6-diethyl-phenyl)-amide	455
683	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-cyclohexyl-phenyl)-amide	447
684	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2,5-dibromo-phenyl)-amide	521
685	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropyl-phenyl)-amide	407
686	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	325
687	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	325
688	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 2-fluoro-benzylamide	309
689	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide	309
690	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	311
691	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (3-chloro-phenyl)-amide	311

692	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide	311
693	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid benzylamide	321
694	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	335
695	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	365
696	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	355
697	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	355
698	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 2-fluoro-benzylamide	339
699	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide	339
700	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (2-chloro-phenyl)-amide	341
701	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (3-chloro-phenyl)-amide	341
702	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide	341
703	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid phenylamide	277
704	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	292
705	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid phenylamide	307
706	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	322
707	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid benzylamide	309

708	1-Benzyl-1H-pyrazole-4-carboxylic acid benzylamide	291
709	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	341
710	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	323
711	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	323
712	1-Benzyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	305
713	1-Benzyl-1H-pyrazole-4-carboxylic acid phenethyl-amide	341
714	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-amide	323
715	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	353
716	1-Benzyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	335
717	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	341
718	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	323
719	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	343
720	1-Benzyl-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide	325
721	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-amide	357
722	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	343
723	1-Benzyl-1H-pyrazole-4-carboxylic acid 2-chloro-benzylamide	325
724	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	357
725	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	339

726	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 2-fluoro-benzylamide	327
727	1-Benzyl-1H-pyrazole-4-carboxylic acid 2-fluoro-benzylamide	309
728	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	353
729	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide	335
730	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide	327
731	1-Benzyl-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide	309
732	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	353
733	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-methoxy-phenyl)-ethyl]-amide	335
734	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	310
735	1-Benzyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	292
736	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	391
737	1-Benzyl-1H-pyrazole-4-carboxylic acid [2-(3-trifluoromethyl-phenyl)-ethyl]-amide	373
738	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-methoxy-benzamide	395
739	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-methanesulfonyl-benzamide	443
740	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	355
741	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	385

742	1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	373
743	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5,6-dimethyl-1H-benzoimidazol-2-yl)-amide	433
744	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-methyl-1H-benzoimidazol-2-yl)-amide	419
745	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-methyl-amide	419
746	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	333
747	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	373
748	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	333
749	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	333
750	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	339
751	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (4-isopropyl-phenyl)-amide	319
752	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	319
753	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	339
754	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide	403
755	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (4-phenyl-butyl)-amide	363
756	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dimethyl-phenyl)-ethyl]-amide	363
757	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide	369

758	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (4-isopropyl-phenyl)-amide	349
759	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (2-o-tolyl-ethyl)-amide	349
760	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	369
761	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	342
762	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	361
763	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid quinolin-8-ylamide	328
764	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	363
765	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	372
766	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	391
767	1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid quinolin-8-ylamide	358
768	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-benzamide	311
769	N-(2-Methyl-5-thiophen-2-yl-2H-pyrazol-3-yl)-benzamide	283
770	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-benzamide	241
771	N-(2-Methyl-5-phenyl-2H-pyrazol-3-yl)-benzamide	277
772	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-benzamide	365
773	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-3-fluoro-benzamide	329
774	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-3-fluoro-benzamide	259
775	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-fluoro-benzamide	383

776	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-2-methoxy-benzamide	341
777	2-Methoxy-N-(2-methyl-5-thiophen-2-yl-2H-pyrazol-3-yl)-benzamide	313
778	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-2-methoxy-benzamide	271
779	2-Methoxy-N-(2-methyl-5-phenyl-2H-pyrazol-3-yl)-benzamide	307
780	N-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-2-methoxy-benzamide	395
781	N-[5-(4-Chloro-phenyl)-2-methyl-2H-pyrazol-3-yl]-3-methanesulfonyl-benzamide	389
782	N-(5-Cyclopropyl-2-methyl-2H-pyrazol-3-yl)-3-methanesulfonyl-benzamide	319
783	3-Methanesulfonyl-N-(2-methyl-5-phenyl-2H-pyrazol-3-yl)-benzamide	355
784	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-methanesulfonyl-phenyl)-urea	458
785	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid 2-methoxy-phenyl ester	411
786	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-methyl-5-trifluoromethyl-1H-benzoimidazol-2-yl)-amide	487
787	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-fluoro-1-methyl-1H-benzoimidazol-2-yl)-amide	437
788	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1,6-dimethyl-1H-benzoimidazol-2-yl)-amide	433
789	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5,6-dichloro-1-methyl-1H-benzoimidazol-2-yl)-amide	487

792	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-methyl-amide	475
793	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-methyl-amide	414
794	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-methyl-amide	425
795	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-methyl-amide	475
796	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-methyl-amide	441
797	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-methyl-amide	425
798	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-fluoro-phenyl)-ethyl]-methyl-amide	425
799	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(3-chloro-phenyl)-ethyl]-methyl-amide	441
800	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-ethanesulfonyl-2-methoxy-phenyl)-methyl-amide	501
801	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-methyl-amide	441
802	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-fluoro-5-methanesulfonyl-phenyl)-methyl-amide	475
803	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid methyl-(3-trifluoromethoxy-phenyl)-amide	463
804	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-methyl-amide	437

805	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzyl-(1-phenyl-ethyl)-amide	483
806	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid methyl-phenethyl-amide	407
807	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-3-ylmethyl-amide	471
808	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide	471
809	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-cyano-ethyl)-pyridin-3-ylmethyl-amide	433
810	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-pyridin-2-yl-piperazin-1-yl)-methanone	435
811	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isopropyl-phenethyl-amide	435
812	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzyl-(1-phenyl-ethyl)-amide	483
813	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl-pyridin-4-ylmethyl-amide	408
814	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(2,5-dihydro-pyrrol-1-yl)-methanone	341
815	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-thiazolidin-3-yl-methanone	361
816	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl-(5-nitro-pyridin-2-yl)-amide	439
817	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid quinolin-6-ylamide	416
818	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-nitro-benzyl)-propyl-amide	466
819	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-[3-(4-methoxy-phenyl)-pyrazol-1-yl]-methanone	446
820	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone	426

821	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-fluoro-phenyl)-thiourea	414
822	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2,5-difluoro-phenyl)-thiourea	432
823	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3,4-dichloro-phenyl)-urea	448
824	1-[1-(4-Chloro-cyclohexa-2,4-dienyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(4-trifluoromethyl-phenyl)-thiourea	464
825	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2,4-dichloro-phenyl)-thiourea	464
826	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid 4-methoxy-phenyl ester	411
827	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid phenyl ester	381
828	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid isobutyl ester	361
829	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2,6-diisopropyl-phenyl)-urea	464
830	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-carbamic acid propyl ester	347
832	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	410
833	5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	482
834	5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	446
835	5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (1H-benzoimidazol-2-yl)-amide	440
836	5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	401

837	5-Trifluoromethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	478
838	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	448
839	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	412
840	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-benzimidazol-2-yl)-amide	406
841	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	367
842	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	444
843	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	427
844	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-benzimidazol-2-yl)-amide	389
845	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	395
846	1-(6-Hydroxy-pyridazin-3-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-trifluoromethyl-benzylamide	431
847	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid methyl-(2-pyridin-2-yl-ethyl)-amide	408
848	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid methyl-pyridin-3-ylmethyl-amide	394
849	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid quinolin-3-ylamide	416
850	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzyl-(3-methanesulfonyl-phenyl)-amide	533

851	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl-(3-methanesulfonyl-phenyl)-amide	471
852	[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-(3-methanesulfonyl-phenyl)-amino]-acetic acid ethyl ester	529
853	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid cyanomethyl-(3-methanesulfonyl-phenyl)-amide	482
854	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-naphthalen-2-ylmethyl-amide	583
855	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-pyridin-3-ylmethyl-amide	534
856	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-pyridin-2-ylmethyl-amide	534
857	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-chloro-benzyl)-(3-methanesulfonyl-phenyl)-amide	567
858	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-pyridin-4-ylmethyl-amide	534
859	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid allyl-(3-methanesulfonyl-phenyl)-amide	483
860	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3,5-dimethyl-isoxazol-4-ylmethyl)-(3-methanesulfonyl-phenyl)-amide	552
861	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid benzyl-[2-(2,6-dichloro-phenyl)-ethyl]-amide	551

862	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-naphthalen-2-ylmethyl-amide	601
863	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-pyridin-3-ylmethyl-amide	552
864	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-pyridin-2-ylmethyl-amide	552
865	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-chloro-benzyl)-[2-(2,6-dichloro-phenyl)-ethyl]-amide	585
866	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-pyridin-4-ylmethyl-amide	552
867	1-Benzyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	394
868	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-phenethyl-urea	408
869	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-[2-(4-fluoro-phenyl)-ethyl]-urea	426
870	Morpholine-4-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	374
871	1-Butyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	360
872	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-m-tolyl-ethyl)-urea	422
873	1-[2-(4-Chloro-phenyl)-ethyl]-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	442
874	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-phenyl-propyl)-urea	422
875	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-cyclopentyl-urea	372

876	1-Benzo[1,3]dioxol-5-ylmethyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	438
877	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-methyl-1-pyridin-3-ylmethyl-urea	409
878	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-methyl-1-(2-pyridin-2-yl-ethyl)-urea	423
879	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide	414
880	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2-fluoro-phenyl)-ethyl]-amide	378
881	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1H-benzimidazol-2-yl)-amide	372
882	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	333
883	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	428
884	1-(3-Chloro-phenyl)-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	414
885	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(4-trifluoromethyl-phenyl)-urea	448
886	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-isoxazol-3-yl-urea	371
887	1-(2-tert-Butyl-phenyl)-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	436
888	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-phenyl-urea	380
889	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-pyrrol-1-yl-phenyl)-urea	445
890	3-(2-Chloro-phenyl)-5-methyl-isoxazole-4-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	480
891	1,3-Bis-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	548

892	4-Acetyl-[1,4]diazepane-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	429
893	1-Allyl-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	344
894	1-(2-Amino-benzyl)-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	409
895	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(4-diethylamino-1-methyl-butyl)-urea	445
896	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-[2-(2-hydroxy-ethoxy)-ethyl]-urea	392
897	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-[2-(ethyl-m-tolyl-amino)-ethyl]-urea	465
898	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-urea	415
899	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-morpholin-4-yl-ethyl)-urea	417
900	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-piperidin-1-yl-ethyl)-urea	415
901	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-pyridin-2-yl-ethyl)-urea	409
902	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-pyrrolidin-1-yl-ethyl)-urea	401
903	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(1H-indazol-6-yl)-urea	420
904	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-pyridin-3-ylmethyl-urea	395
905	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-pyridin-4-ylmethyl-urea	395
906	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-hydroxy-2-phenyl-ethyl)-urea	424
907	1-[2-(4-Amino-phenyl)-ethyl]-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	423

908	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(5-phenyl-2H-pyrazol-3-yl)-urea	446
909	(3-{3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-ureido}-propyl)-carbamic acid tert-butyl ester	461
910	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-imidazol-1-yl-propyl)-urea	412
911	1-(1-Benzyl-pyrrolidin-3-yl)-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	463
912	4-Benzyl-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	463
913	4-(2-Chloro-phenyl)-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	483
914	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1,1-bis-(2-hydroxy-ethyl)-urea	392
915	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-diethylamino-ethyl)-urea	403
916	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(3-diethylamino-propyl)-urea	417
917	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2,3-dimethoxy-benzyl)-urea	454
918	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2,4-dimethoxy-benzyl)-urea	454
919	2,6-Dimethyl-morpholine-4-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	402
920	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1,1-bis-pyridin-2-ylmethyl-urea	486
921	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1,1-bis-pyridin-3-ylmethyl-urea	486
922	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-ethyl-1-(2-hydroxy-ethyl)-urea	376
923	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-ethyl-1-pyridin-4-ylmethyl-urea	423

924	v4-(2-Hydroxy-ethyl)-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	417
925	4-Methyl-[1,4]diazepane-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	401
926	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-methyl-1-(1-methyl-piperidin-4-yl)-urea	415
927	4-Methyl-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	387
928	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-methylsulfanyl-ethyl)-urea	378
929	4-Pyrimidin-2-yl-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	451
930	4-Benzo[1,3]dioxol-5-ylmethyl-piperazine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	507
931	3-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-1-(2-cyano-ethyl)-1-pyridin-3-ylmethyl-urea	448
932	3-Hydroxy-pyrrolidine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	374
933	4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	441
934	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(tetrahydro-furan-2-ylmethyl)-urea	388
935	Thiazolidine-3-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	376
936	Thiomorpholine-4-carboxylic acid [1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-amide	390
937	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-(2-thiophen-2-yl-ethyl)-urea	414
938	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-3-thiophen-2-ylmethyl-urea	400
939	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(4-trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	430

940	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(4-trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	430
941	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	430
942	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-amide	430
943	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-trifluoromethyl-phenyl)-pyrrolidin-3-yl]-amide	414
944	5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid [1-(3-trifluoromethyl-phenyl)-pyrrolidin-3-yl]-amide	414
945	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	440
946	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	424
947	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	384
948	[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(3,4-dihydro-2H-quinolin-1-yl)-methanone	406
949	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methoxy-phenyl)-amide	396
950	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropenyl-phenyl)-amide	406
951	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	381
952	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	462
953	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	451
954	[4-(2-Chloro-phenyl)-piperazin-1-yl]-[1-(6-chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	469
955	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	449

956	(4-Benzyl-piperazin-1-yl)-[1-(6-chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	449
957	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	407
958	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	391
959	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	351
960	(3,4-Dihydro-2H-quinolin-1-yl)-(1-pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone	373
961	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methoxy-phenyl)-amide	363
962	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropenyl-phenyl)-amide	373
963	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	348
964	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	429
965	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	418
966	[4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone	436
967	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	416
968	(4-Benzyl-piperazin-1-yl)-(1-pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone	416
969	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	489
970	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	473
971	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	433

972	(3,4-Dihydro-2H-quinolin-1-yl)-[1-(4-trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	455
973	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methoxy-phenyl)-amide	445
974	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropenyl-phenyl)-amide	455
975	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	430
976	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(2,6-dichloro-phenyl)-ethyl]-amide	511
977	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	500
978	[4-(2-Chloro-phenyl)-piperazin-1-yl]-[1-(4-trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	518
979	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	498
980	(4-Benzyl-piperazin-1-yl)-[1-(4-trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	498
981	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid 2,4-dimethoxy-benzylamide	406
982	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide	390
983	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-fluoro-phenyl)-amide	350
984	(3,4-Dihydro-2H-quinolin-1-yl)-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone	372
985	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methoxy-phenyl)-amide	362

986	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-isopropenyl-phenyl)-amide	372
987	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide	347
988	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	417
989	[4-(2-Chloro-phenyl)-piperazin-1-yl]-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone	435
990	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	415
991	(4-Benzyl-piperazin-1-yl)-(1-pyridin-2-yl-5-trifluoromethyl-1H-pyrazol-4-yl)-methanone	415
992	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	450
993	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	422
994	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide	472
995	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	428
996	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-(4-fluoro-phenyl)-ethyl}-amide	412
997	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide	398
998	4-[[1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester	438
999	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	431
1000	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	401
1001	1-(6-Chloro-pyridin-2-yl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isoquinolin-1-ylamide	417

1002	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	417
1003	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	389
1004	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide	439
1005	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	395
1006	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	379
1007	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide	365
1008	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	411
1009	4-[(1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-benzoic acid ethyl ester	405
1010	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	398
1011	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	368
1012	1-Pyrimidin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isoquinolin-1-ylamide	384
1013	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	499
1014	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	471
1015	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide	521
1016	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	477

1017	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	461
1018	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide	447
1019	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonyl-phenyl)-amide	493
1020	4-[[1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino]-benzoic acid ethyl ester	487
1021	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	480
1022	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	450
1023	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isoquinolin-1-ylamide	466
1024	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-trifluoromethoxy-phenyl)-amide	416
1025	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-tert-butyl-phenyl)-amide	388
1026	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid bis-pyridin-2-ylmethyl-amide	438
1027	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-chloro-phenyl)-ethyl]-amide	394
1028	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide	378
1029	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-fluoro-phenyl)-methyl-amide	364
1030	4-[(1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-benzoic acid ethyl ester	404
1031	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-pyrrol-1-yl-phenyl)-amide	397

1032	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide	367
1033	1-Pyridin-2-yl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid isoquinolin-1-ylamide	383
1034	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [2-(ethyl-m-tolyl-amino)-ethyl]-amide	450
1035	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	448
1036	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	448
1037	1-(1-Benzyl-pyrrolidin-3-yl)-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	463
1038	1-(1-Benzyl-pyrrolidin-3-yl)-3-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-urea	463
1039	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-piperidin-4-yl)-amide	462
1040	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid piperidin-4-ylamide	372
1041	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-sulfamoyl-piperidin-4-yl)-amide	451
1042	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-dimethylsulfamoyl-piperidin-4-yl)-amide	479
1044	4-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-piperidine-1-carboxylic acid ethyl ester	444
1045	{1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-piperidin-4-yl}-carbamic acid tert-butyl ester	472
1046	(4-Amino-piperidin-1-yl)-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	372
1049	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-chloro-phenyl)-amide	399

1050	3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid ethyl ester	437
1052	3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzoic acid	409
1053	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-amide	460
1054	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamoyl-phenyl)-amide	444
1055	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-dimethylsulfamoyl-phenyl)-amide	472
1056	(4-Benzylamino-piperidin-1-yl)-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	462
1057	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-[4-(4-fluoro-benzylamino)-piperidin-1-yl]-methanone	480
1058	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-[4-(4-methoxy-benzylamino)-piperidin-1-yl]-methanone	492
1059	[4-(4-Chloro-benzylamino)-piperidin-1-yl]-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	496
1060	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [1-(4-fluoro-benzyl)-piperidin-4-yl]-amide	480
1061	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [1-(3-chloro-benzyl)-piperidin-4-yl]-amide	496
1062	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [1-(2-fluoro-benzyl)-piperidin-4-yl]-amide	480
1063	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [1-(4-trifluoromethoxy-benzyl)-piperidin-4-yl]-amide	546
1064	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-piperidine-2-carboxylic acid (3-methanesulfonyl-phenyl)-amide	554

1065	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- (4-hydroxy-piperidin-1-yl)-methanone	373
1066	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]- [2-(5-fluoro-1H-benzoimidazol-2-yl)-piperidin-1-yl]- methanone	491
1067	[2-(1H-Benzoimidazol-2-yl)-piperidin-1-yl]-[1-(4-chloro- phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	473
1068	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-methanesulfonyl-phenyl)-amide	427
1069	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (3-methanesulfonyl-phenyl)-amide	445
1070	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	377
1071	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid phenethyl-amide	395
1072	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid benzyl-methyl-amide	377
1073	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid benzyl-methyl-amide	395
1074	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	431
1075	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid 3-trifluoromethyl-benzylamide	449
1076	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carbonyl]-piperidine-2-carboxylic acid phenethyl-amide	504
1077	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carbonyl]-piperidine-2-carboxylic acid benzyl-methyl- amide	504
1078	1-[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carbonyl]-piperidine-2-carboxylic acid 3-trifluoromethyl- benzylamide	558
1079	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4- carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	446

1080	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	464
1081	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-methyl-amide	512
1082	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-diisopropylamino-pyrimidin-2-yl)-amide	450
1083	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-diisopropylamino-pyrimidin-2-yl)-amide	468
1084	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (5-diisopropylamino-pyrimidin-2-yl)-amide	516
1085	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamoyl-phenyl)-amide	428
1086	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamoyl-phenyl)-amide	446
1087	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamoyl-phenyl)-amide	494
1088	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-pyrimidin-5-yl)-amide	443
1089	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-thiazol-2-yl-phenyl)-amide	448
1090	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl)-phenyl]-amide	461
1091	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-benzooxazol-2-yl-phenyl)-amide	482
1092	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-carbamoyl-phenyl)-amide	408
1093	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-dimethylamino-phenyl)-amide	408

1094	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-hydroxy-ethanesulfonyl)-phenyl]-amide	473
1095	4- {[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino} -piperidine-1-carboxylic acid tert-butyl ester	472
1096	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	429
1097	(4-Benzyl-piperazin-1-yl)-[1-(3-fluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	432
1098	1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	350
1099	Biphenyl-3-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	353
1100	Biphenyl-4-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	353
1101	4'-Chloro-biphenyl-3-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	387
1102	3- {[1-(3-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino} -piperidine-1-carboxylic acid tert-butyl ester	456
1103	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	447
1104	(4-Benzyl-piperazin-1-yl)-[1-(3,4-difluoro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	450
1105	1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	368
1106	3- {[1-(3,4-Difluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino} -piperidine-1-carboxylic acid tert-butyl ester	474

1107	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(morpholine-4-sulfonyl)-phenyl]-amide	514
1108	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	495
1109	1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid pyridin-4-ylamide	416
1110	3-[[1-(4-Trifluoromethoxy-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-piperidine-1-carboxylic acid tert-butyl ester	522
1111	Methanesulfonic acid 1-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-piperidin-4-yl ester	451
1112	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methylsulfamoyl-phenyl)-amide	458
1113	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-pyridin-2-yl-phenyl)-amide	442
1114	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-pyridin-3-yl-phenyl)-amide	442
1115	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-pyridin-4-yl-phenyl)-amide	442
1116	1-(4-Fluoro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-sulfamoyl-phenyl)-amide	428
1117	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-trifluoromethanesulfonyl-phenyl)-amide	497
1118	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfonylamino-phenyl)-amide	458
1119	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2H-tetrazol-5-yl)-phenyl]-amide	433
1120	[(3-[[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-phenyl)-imino-methyl]-carbamic acid tert-butyl ester	

1121	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-carbamimidoyl-phenyl)-amide	
1122	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-amino-phenyl)-amide	380
1123	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-ureido-phenyl)-amide	
1127	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-sulfamoyl-phenyl)-amide	444
1130	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-acetylamino-phenyl)-amide	422
1131	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-cyclopropylsulfamoyl-phenyl)-amide	484
1132	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-pyridin-2-ylmethyl-piperazin-1-yl)-methanone	449
1133	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-pyridin-3-ylmethyl-piperazin-1-yl)-methanone	449
1134	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone	449
1135	[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-[4-(1-methyl-piperidin-3-ylmethyl)-piperazin-1-yl]-methanone	469
1136	2-Phenyl-2H-pyrazole-3-carboxylic acid pyridin-4-ylamide	264
1137	(4-Benzyl-piperazin-1-yl)-(2-phenyl-2H-pyrazol-3-yl)-methanone	346
1138	2-Phenyl-2H-pyrazole-3-carboxylic acid (3-methanesulfonyl-phenyl)-amide	341
1139	2-Phenyl-2H-pyrazole-3-carboxylic acid (1H-benzoimidazol-2-yl)-amide	303
1140	2-Phenyl-2H-pyrazole-3-carboxylic acid 3-trifluoromethyl-benzylamide	345
1141	2-Phenyl-2H-pyrazole-3-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl)-amide	343

1142	2-Phenyl-2H-pyrazole-3-carboxylic acid (3-sulfamoyl-phenyl)-amide	342
1143	2-Phenyl-2H-pyrazole-3-carboxylic acid (1-benzyl-piperidin-4-yl)-amide	360
1144	2-Phenyl-2H-pyrazole-3-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	346
1145	2-Phenyl-2H-pyrazole-3-carboxylic acid (1-benzyl-pyrrolidin-3-yl)-amide	346
1146	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methylsulfanyl-phenyl)-amide	411
1147	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-methanesulfinyl-phenyl)-amide	427
1148	3-{{1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonic acid	445
1151	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(methanesulfonylimino-phenoxy-methyl)-amino]-phenyl}-amide	577
1152	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(amino-methanesulfonylimino-methyl)-amino]-phenyl}-amide	500
1153	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(methanesulfonylimino-methylamino-methyl)-amino]-phenyl}-amide	514
1154	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(cyclopropylamino-methanesulfonylimino-methyl)-amino]-phenyl}-amide	540
1155	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(dimethylamino-methanesulfonylimino-methyl)-amino]-phenyl}-amide	528
1156	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-{{(isopropyl-methyl-amino)-methanesulfonylimino-methyl]-amino}-phenyl)-amide	556

1157	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2,4-dimethoxy-benzylsulfamoyl)-phenyl]-amide	594
1158	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-piperidin-1-yl-ethylsulfamoyl)-phenyl]-amide	555
1159	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(3-diethylamino-propylsulfamoyl)-phenyl]-amide	557
1160	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2,3-dimethoxy-benzylsulfamoyl)-phenyl]-amide	594
1161	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[3-(2-oxo-pyrrolidin-1-yl)-propylsulfamoyl]-phenyl}-amide	569
1162	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[2-(ethyl-m-tolyl-amino)-ethylsulfamoyl]-phenyl}-amide	605
1163	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(3-hydroxy-pyrrolidine-1-sulfonyl)-phenyl]-amide	514
1164	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-butylsulfamoyl-phenyl)-amide	500
1165	[3-(3-{[1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carbonyl]-amino}-benzenesulfonylamino)-propyl]-carbamic acid tert-butyl ester	601
1166	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(3-hydroxy-pyrrolidine-1-sulfonyl)-phenyl]-amide	514
1167	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-hydroxy-propylsulfamoyl)-phenyl]-amide	502


1168	(4-Benzyl-piperazin-1-yl)-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	448
1169	(4-Benzyl-4-hydroxy-piperidin-1-yl)-[1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazol-4-yl]-methanone	463
1170	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(1-ethyl-pyrrolidin-2-ylmethyl)-sulfamoyl]-phenyl}-amide	555
1171	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-diethylamino-ethylsulfamoyl)-phenyl]-amide	543
1172	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[2-(4-amino-phenyl)-ethylsulfamoyl]-phenyl}-amide	563
1173	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-pyrrolidin-1-yl-ethylsulfamoyl)-phenyl]-amide	541
1174	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(pyridin-3-ylmethyl)-sulfamoyl]-phenyl}-amide	535
1175	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(2-dimethylamino-ethylsulfamoyl)-phenyl]-amide	515
1176	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(thiomorpholine-4-sulfonyl)-phenyl]-amide	530
1177	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(4-methyl-[1,4]diazepane-1-sulfonyl)-phenyl]-amide	541
1178	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid [3-(4-methyl-piperazine-1-sulfonyl)-phenyl]-amide	527

1179	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[2-(3-chloro-phenyl)-ethylsulfamoyl]-phenyl}-amide	582
1180	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[methyl-(2-pyridin-2-yl-ethyl)-sulfamoyl]-phenyl}-amide	563
1181	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-ethylsulfamoyl-phenyl)-amide	472
1182	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid {3-[(2-hydroxy-ethyl)-methyl-sulfamoyl]-phenyl}-amide	502
1183	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (3-diethylsulfamoyl-phenyl)-amide	500
1184	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (6-methanesulfonyl-benzothiazol-2-yl)-amide	500
1185	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-methyl-3-sulfamoyl-phenyl)-amide	458
1186	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-sulfamoylmethyl-phenyl)-amide	458
1187	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (2-chloro-5-sulfamoyl-phenyl)-amide	478
1188	1-(4-Chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid (4-methyl-5-sulfamoyl-thiazol-2-yl)-amide	465

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to included within the spirit and purview of this application and are considered within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

WHAT IS CLAIMED IS:

1. A compound having the formula:




or a pharmaceutically acceptable salt thereof, wherein

R¹ and R³ are each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;

R² is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

Y is a member selected from:



wherein

X is a member selected from O, S and NR⁸

wherein

R⁸ is a member selected from the group of hydrogen, cyano, nitro, alkyl, acyl, aryl and SO₂R⁹

wherein


R⁹ is a member selected from alkyl, aryl, heteroaryl and heterocycloalkyl;

R⁴ and R⁵ are each members independently selected from hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl with the proviso that if R⁴ is hydrogen, R⁵ is not hydrogen; and R⁴ and R⁵ taken together with the nitrogen atom to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring;


R⁶ is a member selected from hydrogen, (C₁-C₆)alkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₁-C₆)heteroalkyl; and

30 R^7 is a member selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-
 31 C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-
 32 C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-
 33 C₈)heterocycloalkyl and amino(C₁-C₅)alkyl, and
 34 and R^6 and R^7 together with the atoms to which they are
 35 attached optionally form a 4- to 8-membered
 36 heterocycloalkyl ring.

1 2. The compound of claim 1 having the formula:



1 3. The compound of claim 2 wherein Y has a formula which is a
 2 member selected from:



1 4. The compound of claim 3 wherein
 2 R^1 and R^3 are each members independently selected from hydrogen, (C₁-
 3 C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl and (C₁-
 4 C₅)heteroalkyl; and
 5 X is O.


1 5. The compound of claim 4 wherein R^2 is a member selected from
 2 aryl and heteroaryl.

1 6. The compound of claim 5 wherein R^3 is hydrogen.


1 7. The compound according to claim 6 wherein R^1 is a member
 2 selected from hydrogen, (C₁-C₄)alkyl, and (C₁-C₄)haloalkyl.

1 8. The compound according to claim 3 wherein R^4 is a member
 2 selected from heteroaryl and heterocycloalkyl; and
 3 R^4 and R^5 , together with the nitrogen to which they are bonded are
 4 optionally joined to form a 4- to 8-membered heterocycloalkyl ring system.

9. The compound according to claim 8, wherein R^4 and R^5 taken together with the nitrogen to which they are attached form a member selected from:




10. A compound having the formula:



or a pharmaceutically acceptable salt thereof, wherein

R^1 and R^3 are each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;
 R^2 is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;
 Y is a member selected from:



wherein

X is a member selected from O, S and NR^8


wherein

R^8 is a member selected from hydrogen, cyano, nitro, alkyl, acyl, aryl and SO_2R^9

wherein

R^9 is a member selected from alkyl, aryl, heteroaryl and heterocycloalkyl;

R^4 has a formula which is a member selected from:



wherein

n is an integer from 0 to 4;

k is an integer from 1 to 3;

R^{2a} and R^{2b} are members independently selected from hydrogen and (C₁-C₄)alkyl, and R^{2a} and R^{2b} taken together with the carbon atom to which they are attached optionally form a 3- to 8-membered carbocyclic or heterocycloalkyl ring;

M is a member selected from NR¹⁰, O and S

wherein

R¹⁰ is a member selected from hydrogen, (C₁-C₆) alkyl, (C₁-C₈) heteroalkyl aryl, heteroaryl and (C₃-C₈) cycloalkyl;

A, B, D, E and G are independently members selected from N, N-oxide and CR¹¹ with the proviso that at most three of A, B, D, E and G is N; and at most one of A, B, D, E and G is N-oxide

wherein

R¹¹ is a member selected from hydrogen, halo, amino, hydroxy, cyano, nitro, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)heteroalkyl, aryl, heteroaryl, (C₃-C₈)heterocycloalkyl, alkoxy, acyl, -C(NR¹²)R¹³, -SO₂R¹⁵, -SO₂NR¹³R¹⁴, -NR¹²SOR¹⁵, -NR¹²SO₂NR¹³R¹⁴, -NR¹²C(N-CN)NR¹³R¹⁴, -NR¹²C(N-SO₂R¹⁵)NR¹³R¹⁴, -NR¹²C(N-COR¹⁵)NR¹³R¹⁴, -CONR¹³R¹⁴, -NR¹²(C=CH-NO₂)NR¹³R¹⁴, -NR¹²CONR¹³R¹⁴, -NR¹²CO-OR¹⁵, -OCONR¹³R¹⁴ and R¹¹ and R^{2a} taken together with the carbon atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl group with the proviso that A is CR¹¹

wherein

R^{11a} is a member selected from (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, (C₃-C₈)heterocycloalkyl, aryl and heteroaryl;

R¹², R¹³ and R¹⁴ are members independently selected from hydrogen, (C₁-C₈)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, (C₃-


58 C₈)heterocycloalkyl, aryl(C₁-C₄)alkyl,
59 heteroaryl(C₁-C₄)alkyl, amino(C₁-C₄)alkyl and
60 when R¹³ and R¹⁴ are attached to the same nitrogen
61 atom, they are optionally combined to form a 5-, 6-
62 or 7-membered ring;
63 R¹⁵ is a member selected from (C₁-C₈)alkyl, (C₃-
64 C₈)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl
65 and (C₃-C₈)heterocycloalkyl;
66 R⁵ is a member selected from hydrogen and (C₁-C₄)alkyl; and R⁵ and R¹¹
67 taken together with the atoms to which that are attached optionally
68 form a 4- to 8-membered heterocycloalkyl ring with the proviso
69 that A is CR¹¹
70 R⁶ is a member selected from hydrogen, (C₁-C₆)alkyl, aryl, heteroaryl,
71 aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₁-C₆)heteroalkyl;
72 and
73 R⁷ is a member selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-
74 C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl,
75 heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-C₈)heterocycloalkyl
76 and amino(C₁-C₅)alkyl, and R⁶ and R⁷ taken together with the
77 atoms to which they are attached optionally form a 4- to 8-
78 membered heterocycloalkyl ring.

1 11. The compound of claim 10 wherein R¹ and R³ are each members
2 independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl
3 and (C₁-C₅)heteroalkyl; and X is O.

1 12. The compound of claim 11 wherein R² is a member selected from
2 aryl and heteroaryl.

1 13. The compound of claim 11 wherein one only of A, B, C, D or E is
2 an N or N-oxide.

1 14. A compound having the formula:
2




or a pharmaceutically acceptable salt thereof, wherein


R^1 and R^3 are each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;

R^2 is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

Y is a member selected from:



R^4 has a formula which is a member selected from:



wherein

W is a member selected from S, SO and SO₂;

n is an integer from 0 to 4;

R^{2a} and R^{2b} are members independently selected from hydrogen and (C₁-C₄)alkyl, and R^{2a} and R^{2b} taken together with the carbon atom to which they are attached optionally form a 3- to 8-membered carbocyclic or heterocycloalkyl ring;

R^{15} is a member selected from (C₁-C₄)alkyl, (C₁-C₆)alkenyl, (C₃-C₇)cycloalkyl, aryl, heteroaryl, (C₁-C₈)heteroalkyl, NR¹⁶R¹⁷

wherein

R^{16} and R^{17} are members independently selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, (C₃-C₈)heterocycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino(C₁-C₄)alkyl, with the proviso that when R^{15} is amino W is SO₂;

29 T¹, T², T³ and T⁴ are each members independently selected from hydrogen,
30 halo, amino, cyano, nitro, (C₁-C₄)alkyl, (C₃-C₈)cycloalkyl, (C₁-
31 C₄)haloalkyl, alkoxy, fluoro(C₁-C₄)alkoxy, (C₁-C₇)cycloalkyl, (C₁-
32 C₇)heteroalkyl, aryl and heteroaryl, and T¹ and T² taken together
33 with the carbon atoms to which they are attached optionally form a
34 4- to 8-membered carbocyclic or heterocycloalkyl ring; T² and T³
35 taken together with the carbon atoms to which they are attached
36 optionally form a 4- to 8-membered carbocyclic or
37 heterocycloalkyl ring; T³ and R¹⁵ taken together with the atoms to
38 which they are attached optionally form a 4- to 8-membered
39 carbocyclic or heterocycloalkyl ring; and T⁴ and R¹⁵ taken together
40 with the atoms to which they are attached optionally form a 4- to 8-
41 membered carbocyclic or heterocycloalkyl ring; and
42 R⁵ is a member selected from hydrogen and (C₁-C₄)alkyl; R⁵ and T¹ taken
43 together with the atoms to which they are attached optionally form
44 a 4- to 8-membered heterocycloalkyl ring, and R⁵ and T⁴ taken
45 together with the atoms to which they are attached optionally form
46 a 4- to 8-membered heterocycloalkyl ring.

1 15. The compound of claim 14 wherein R¹ and R³ are each members
2 independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl
3 and (C₁-C₅)heteroalkyl; and X is O.


1 16. The compound of claim 14 wherein R² is a member selected from
2 aryl and heteroaryl.

1 17. The compound of claim 15 wherein W is SO₂; and R¹¹ is selected
2 from substituted or unsubstituted (C₁-C₄)alkyl and NR¹⁶R¹⁷; and n is 0.

1 18. A method of decreasing ion flow through voltage-dependent
2 sodium channels in a cell, said method comprising contacting said cell with a sodium
3 channel-inhibiting amount of a compound comprising a pyrazolyl moiety.

1 19. The method according to claim 18, wherein said cell is in a human.

20. A method of decreasing ion flow through voltage-dependent sodium channels in a cell, said method comprising contacting said cell with a sodium channel-inhibiting amount of a compound of the formula:




or a pharmaceutically acceptable salt thereof, wherein

R¹ and R³ are each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;

R² is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

Y is a member selected from:



wherein

X is a member selected from O, S and NR⁸

wherein

R⁸ is a member selected from the group of hydrogen, cyano, nitro, alkyl, acyl, aryl and SO₂R⁹

wherein

R⁹ is a member selected from alkyl, aryl, heteroaryl and heterocycloalkyl;

R⁴ and R⁵ are each members independently selected from

hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl,

heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl with

the proviso that if R⁴ is hydrogen, R⁵ is not hydrogen; and

R⁴ and R⁵ taken together with the nitrogen atom to which


they are attached optionally form a 4- to 8-membered

heterocycloalkyl ring;

29 R^6 is a member selected from hydrogen, (C₁-C₆)alkyl, aryl,
 30 heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and
 31 (C₁-C₆)heteroalkyl; and
 32 R^7 is a member selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-
 33 C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-
 34 C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-
 35 C₈)heterocycloalkyl and amino(C₁-C₅)alkyl, and
 36 and R^6 and R^7 together with the atoms to which they are
 37 attached optionally form a 4- to 8-membered
 38 heterocycloalkyl ring.

1 21. A method of treating a central or peripheral nervous system
 2 disorder or condition through inhibition of a voltage-dependent sodium channel, said
 3 method comprising administering to a subject in need of such treatment, an effective
 4 amount of a compound comprising a pyrazolyl moiety.

1 22. The method according to claim 21, said compound having the
 2 formula:




3
 4 or a pharmaceutically acceptable salt thereof, wherein

5 R^1 and R^3 are each members independently selected from hydrogen, (C₁-
 6 C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl,
 7 amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;

8 R^2 is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl,
 9 aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

10 Y is a member selected from:



11
 12 wherein

13 X is a member selected from O, S and NR⁸

14 wherein

R^8 is a member selected from the group of hydrogen, cyano, nitro, alkyl, acyl, aryl and SO_2R^9

wherein

R^9 is a member selected from alkyl, aryl, heteroaryl and heterocycloalkyl;


R^4 and R^5 are each members independently selected from hydrogen, (C_1-C_{10}) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_8) heteroalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, heteroaryl (C_1-C_4) alkyl and (C_3-C_8) heterocycloalkyl with the proviso that if R^4 is hydrogen, R^5 is not hydrogen; and R^4 and R^5 taken together with the nitrogen atom to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring;

R^6 is a member selected from hydrogen, (C_1-C_6) alkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, heteroaryl (C_1-C_4) alkyl and (C_1-C_6) heteroalkyl; and

R^7 is a member selected from (C_1-C_7) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_7) alkenyl, (C_1-C_6) heteroalkyl, aryl, heteroaryl, aryl (C_1-C_4) alkyl, heteroaryl (C_1-C_4) alkyl, amino, alkoxy, (C_3-C_8) heterocycloalkyl and amino (C_1-C_5) alkyl, and R^6 and R^7 together with the atoms to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring.

23. The method according to claim 20, wherein said disorder is pain selected from inflammatory pain, neuropathic pain and combinations thereof.

24. A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:




or a pharmaceutically acceptable salt thereof, wherein

R^1 and R^3 are each members independently selected from hydrogen, (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₄)haloalkyl, (C₁-C₆)heteroalkyl, amino, halo, cyano, nitro, hydroxy, aryl and heteroaryl;

R^2 is a member selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₇)cycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

Y is a member selected from:



wherein

X is a member selected from O, S and NR⁸

wherein

R^8 is a member selected from the group of hydrogen, cyano, nitro, alkyl, acyl, aryl and SO₂R⁹

wherein

R^9 is a member selected from alkyl, aryl, heteroaryl and heterocycloalkyl;

R^4 and R^5 are each members independently selected from

hydrogen, (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₈)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₃-C₈)heterocycloalkyl with the proviso that if R^4 is hydrogen, R^5 is not hydrogen; and R^4 and R^5 taken together with the nitrogen atom to which they are attached optionally form a 4- to 8-membered heterocycloalkyl ring;

R^6 is a member selected from hydrogen, (C₁-C₆)alkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl and (C₁-C₆)heteroalkyl; and






R^7 is a member selected from (C₁-C₇)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₇)alkenyl, (C₁-C₆)heteroalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, heteroaryl(C₁-C₄)alkyl, amino, alkoxy, (C₃-C₈)heterocycloalkyl and amino(C₁-C₅)alkyl, and

35 and R⁶ and R⁷ together with the atoms to which they are
36 attached optionally form a 4- to 8-membered
37 heterocycloalkyl ring.
38

FIG. 1A

compound #	Structure	MZ
790		405
791		494
831		482
1043		516
1047		439
1048		467
1124		524
1125		461

FIG. 1B

1126		447
1128		475
1129		487
1149		459
1150		487

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037274 A3

- (51) International Patent Classification⁷: C07D 231/10, 401/12, A61K 31/415
- (21) International Application Number: PCT/US02/35172
- (22) International Filing Date:
1 November 2002 (01.11.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/335,958 1 November 2001 (01.11.2001) US
- (71) Applicant (*for all designated States except US*): ICA-GEN, INC. [US/US]; Suite 460, 4222 Emperor Boulevard, Durham, NC 27703 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): ATKINSON, Robert, Nelson [US/US]; 11908 Radner Way, Raleigh, NC 27613 (US). GROSS, Michael, Francis [US/US]; 6200 Chesden Drive, Durham, NC 27713 (US).
- (74) Agents: MANN, Jeffrey, S. et al.; Townsend Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— *of inventorship (Rule 4.17(iv)) for US only*
- Published:**
— *with international search report*
- (88) Date of publication of the international search report:
30 October 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PYRAZOLE-AMIDES AND-SULFONAMIDES

(57) Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazole-amides and -sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.



WO 03/037274 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/35172

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : CO7D 231/10; 401/12; A61K 31/415 US CL : 548/364.1, 374.1; 514/406 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 548/364.1, 374.1; 514/406 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, EAST		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,620,865 (BECK et al) 4 Nov 1986 (4.11.1986), column 1-7.	1-17
A	US 6,300,363 (Stevens et al) 9 Oct 2001 (9.10.2001), whole article especially column 1-5.	1-24
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 16 May 2003 (16.05.2003)		Date of mailing of the international search report 26 JUN 2003
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer Golam M Shameem Telephone No. (703) 308-1235

Testimony
United States Senate Committee on the Judiciary
Paying Off Generics to Prevent Competition with Brand Name Drugs
January 17, 2007

Michael Wroblewski
Consumers Union, Non-Profit Publisher of Consumer Reports

United States Senate Committee on the Judiciary
“Paying Off Generics to Prevent Competition with Brand Name Drugs:
Should it Be Prohibited?”

January 17, 2007

Statement of Michael Wroblewski
Project Director, Consumer Education and Outreach
Consumers Union, the Non-Profit Publisher of Consumer Reports

Mr. Chairman, Members of the Committee:

Thank you for the invitation to testify today. Consumers Union is the independent non-profit publisher of Consumer Reports. Consumers Union investigates and reports extensively on the issues surrounding the costs, safety, and effectiveness of prescription drugs so that we can provide consumers with expert, non-biased advice to help them manage their health.

In answer to the question that motivated this hearing, “Whether paying off generics to prevent competition with brand-name drugs should be prohibited?” Consumers Union responds with an emphatic “Yes!” Consumers Union strongly supports prompt Congressional action to create a bright line rule to end the use of patent settlements that include compensation from brand-name companies to generic drug applicants in order to restrict generic market entry. These types of settlements should be declared “unfair methods of competition.”

These settlements restrict generic competition at the expense of consumers, whose access to lower-priced generic drugs may be deferred for years. These settlements also jeopardize the health of millions of Americans who have difficulty obtaining safe and effective medicines at affordable prices. In light of the recent increased use of these agreements, we urge prompt Congressional action to end this practice.

This testimony first discusses why generic drugs are critical to affordable health care today and how Consumers Union is educating its readers and the public about the substantial benefits of generic drugs. The testimony then explains how the dynamics of generic drug competition create powerful incentives for brand-name and generic companies to settle patent litigation in a way that harms consumers. The Hatch-Waxman Act (the Act), which governs the approval of generic drugs, exacerbates these incentives. The testimony highlights why continued reliance on the courts to provide consumers with timely relief is misplaced. The testimony also describes Consumers Union’s support of several other legislative changes to speed generic entry, including: (a) breaking the bottleneck that can occur when generic applicants cannot obtain decisions on the merits concerning patent infringement, (b) clarifying the law to provide for the development of generic versions of complex molecular biologic medicines, (c) clearing the backlog of generic applications at the FDA, and (d) eliminating the abuse of citizen petitions in the generic drug approval process.

I. Generic Drugs Can Help Dampen High Health Care Costs Now

Health care costs continue to surge at double or triple the rate of general inflation, in part due to the high cost and rate of inflation of brand-name prescription drugs. Generic drugs can dampen health inflation by providing equally safe and effective medicine at a far lower price—often prices up to 70 percent or less of the brand name drug.

New generic drug entry in 2006 illustrates the substantial savings that generic drugs can have on health-care spending. During 2006, the cholesterol-lowering drugs Zocor and Pravachol, the antidepressants Zoloft and Wellbutrin, and the nasal spray Flonase all went generic. Employers, governments, and patients paid \$9.4 billion for these drugs in 2005 (the year before generic entry). Because generic drugs can be up to 70% less expensive than brand-name drug price, there is a potential annual savings of \$6.6 billion on those five drugs alone. This year and in 2008, several brand-drugs are expected to go generic, including blockbuster drugs with over \$1 billion in annual sales such as Prevacid (used to treat heartburn), Imitrex (to treat migraine headaches), Zyrtec (to treat allergies), and Effexor (to treat depression). The consumer savings once generic versions of these drugs are available will be immense.

Consumer Reports strongly encourages the use of generics as a way for consumers to save money while obtaining quality health care. We have made a major organizational commitment to educate consumers about generic drugs and to help consumers obtain reliable, easy-to-understand advice about the safest, most effective, and lowest cost prescription drugs available. In December 2004, Consumers Union launched Consumer Reports Best Buy Drugssm, a free public education project. Attached to this testimony are two sample Best Buy Drugs summary reports on prescription drugs to reduce cholesterol and to relieve heartburn. We currently provide information for 16 different classes of medicine, and we plan to expand to additional classes in the near future.

The goals of Best Buy Drugs are to:

- improve the quality of care by ensuring people get the safest, most effective drugs with the least side effects;
- improve access by helping consumers choose drugs that are most affordable (taking into account effectiveness, side effects, safety, and price); and
- help consumers and taxpayers by reducing the cost of health insurance, consumers' out-of-pocket expenses, and Medicare and Medicaid.

We estimate that a consumer who switches from a highly advertised, high-priced brand name drug to a Best Buy Drug can often save between \$1,000 and \$2,000 a year. Approximately 100,000 Consumer Reports Best Buy Drugssm reports are downloaded each month, including about 20,000 in Spanish. In addition to our Web site www.CRBESTBUYDRUGS.org, we distribute print versions of our reports in five states with the help of pharmacists, senior organizations, doctors, and libraries. The Best Buy Drugs website also provides additional information describing how Best Buy Drugs operates and the rigorous evidence-based review that is used to derive the "Best Buy Drug" in each class of medicine.

Consumer Reports also has been active in reporting on the consumer benefits of generic drugs. Most recent, Consumer Reports published a report in its November 2006 issue that explained how cash prices for generic drugs vary widely at different types of pharmacies. The report concluded that for five highly prescribed generic drugs (fluoxetine, lisinopril, lovastatin, metformin, and warfarin), median prices at mass merchant and online pharmacies were approximately 20 to 50 percent less expensive than prices at supermarket and drug chain pharmacies. We urged our readers to shop around for the best deals.

II. The Dynamics of Generic Drug Competition Create Powerful Incentives for Brand-Name and Generic Companies to Settle Patent Litigation in A Way that Thwarts the Objectives of the Hatch-Waxman Act.

The economics surrounding generic entry create powerful incentives for brand-name and generic companies to enter into these types of patent settlements. These incentives are created because the total profits available to the brand-name company prior to generic entry exceed the total profits of both the brand-name and generic applicant after generic entry. As a result, the brand-name company has a powerful economic incentive to pay the generic applicant something more than it would earn by entry with its generic product, because the sum the brand-name company pays will still be less than it would lose if the generic applicant did enter the market. Likewise, the generic applicant who is sued for patent infringement can earn more by entering into a settlement in which it agrees to defer market entry than it could earn by winning its patent challenge and competing in the market. In short, when these payments are

allowed, the generic company may obtain more by settlement than it could have obtained by outright victory in the patent case.

A. The Hatch-Waxman Act Exacerbates the Incentive to Settle Patent Litigation with Compensation Paid to the Generic Applicant.

When Congress enacted the Hatch-Waxman Act, it represented a compromise between making available more low-cost generic drugs, while at the same time restoring patent life lost due to the length of FDA brand-name drug approval process. To accomplish this goal, Congress created a number of industry-specific incentives to speed generic entry. In order to see how these incentives work, and their effects on the dynamic of patent settlements, it is necessary to understand three unique features of the Act: a paragraph IV certification, the 30-month stay period, and the 180-day marketing exclusivity provision.

The Act establishes a procedure for accelerated FDA approval of generic drugs through the use of an “Abbreviated New Drug Application” (ANDA). The Act requires a generic applicant to show that its generic drug is “bioequivalent” to the brand-name drug. The generic drug manufacturer does not have to replicate the costly safety and efficacy tests for its drug; rather, the Act permits the generic company to rely on the safety and efficacy tests of the brand-name drug product.

One of the most important features of this application process is if the generic applicant seeks prompt approval of its generic drug, it must certify that its generic drug product does not infringe on the patents claiming the brand-name drug product, or that patents claiming the brand-name drug product are invalid. The Act names this a “paragraph IV” certification.

A generic applicant that makes a paragraph IV certification must notify the patent holder. If the patent holder does not bring an infringement action against the generic applicant within 45 days, the FDA may approve the ANDA, assuming the other regulatory requirements are met. Alternatively, if the brand-name company brings an infringement action during the 45-day period after notification, the patent owner is entitled to an automatic stay of FDA approval of the ANDA for 30 months (the 30-month stay). This process provides the brand-name company and the generic applicant an opportunity to litigate patent issues before the generic drug has entered the market and incurred any damage exposure.

The Act provides that the generic applicant to file the first ANDA containing a paragraph IV certification (the “first filer”) for a particular brand-name drug is entitled to 180-days of marketing exclusivity. During this period, the Food and Drug Administration may not approve a subsequently filed ANDA for the same brand-name drug product. The 180-day period starts once the first filed generic applicant begins commercial marketing of its generic drug product. The real effect of this exclusivity period is that the FDA is prohibited from approving any subsequently filed ANDA for the same brand-drug product until the first filer’s 180-day period of marketing exclusivity expires. The 180-day exclusivity period is an important incentive Congress provided to would-be generic entrants to encourage them to challenge weak or questionable patents claiming brand-name drug products or to design around a brand-name drug’s patent.

This regulatory structure exacerbates the economic incentives underlying patent settlements between brand-name companies and generic applicants discussed above. A settlement between the brand-name company and the first filer will avoid the brand-name company’s lost profit potential. In addition, the 180-day marketing exclusivity provision blocks entry by subsequently filed generics until 180 days after the first filer actually begins commercial marketing. Unfortunately for consumers, the first filer has a powerful incentive to accept a settlement because it will not only get the brand name company’s compensation, but it retains its 180-day marketing exclusivity when it does enter at a later date. Although both the brand-name company and the generic company are better off with the settlement, consumers lose the possibility of an earlier generic entry, either because the generic company would have prevailed in the lawsuit or the parties would have negotiated a settlement with an earlier entry date but no payment.

B. These Settlements Are Contrary to the Purpose of the Hatch-Waxman Act.

The irony, of course, is that the purpose of the ANDA application process was to speed the entry of generic drugs. This policy was reaffirmed in 2003 when Congress amended the Hatch-Waxman Act in the Medicare Modernization Act. As the Senate Report explained, those amendments sought in part to stamp out the “abuse” of the Hatch-Waxman Act resulting from “pacts between big pharmaceutical firms and makers of generic versions of brand name drugs, that are intended to keep lower cost drugs off the market.” Indeed, Senator Hatch, one of the Act’s co-authors, stated during the debate over these amendments that “[a]s a coauthor of the Drug Price Competition and Patent Term Restoration Act, I can tell you that I find these types of reverse payment collusive arrangements appalling. I must concede, as a drafter of the law, that we came up short in our draftsmanship. We did not wish to encourage situations where payments were made to generic firms not to sell generic drugs and not to allow multi-source generic competition.”

C. Experience Shows that Brand-Name Companies and Generic Applicants Do Not Need to Use Payments for Delay to Settle Patent Litigation.

As noted above, the FTC has reported that these types of patent settlements reappeared in 2005, after a six year hiatus. Two observations can be made from this fact. First, the FTC reported that in 1999 its investigations into the legality of these types of settlement agreements became public. The result of this public knowledge was that brand-name and generic companies stopped entering into patent settlement agreements with these terms. Second, brand-name and generic companies continued to settle patent disputes during this period (roughly from 1999 to 2005), when many industry participants believed it to be anticompetitive to enter into these types of patents settlements. This fact undermines any contention now that these payments are necessary to settle patent litigation.

III. The Courts are Unlikely to Provide Timely Relief to Consumers.

We encourage Congress to act now to end the use of these types of settlement agreements because it is unlikely the federal courts will provide consumers relief in a timely manner. Two recent appellate court decisions have taken a lenient view of these types of patent settlements, with one of the courts rejecting the reasoned antitrust analysis of these settlements put forth by the FTC. Both courts have, in essence, held that these settlements are legal unless the patent was obtained by fraud or that the infringement suit itself was a sham. These courts relied on the presumptive validity of a patent to support the conclusion that any settlement which does not exceed the exclusionary scope of a patent also must be valid. The upshot of these court rulings is that a patent holder can pay whatever it takes to buy off a potential challenger during the life of the patent. In one sense, court approval of these types of payments will convert Hatch-Waxman into a vehicle for facilitating the collection of “greenmail” by generic applicants.

These rulings are based on two faulty premises. First these courts seem to require that unless the patent can be proved to be invalid or not infringed, a court cannot declare a settlement illegal. This test, as the FTC discussed in its Schering opinion, may be good in theory but, it is nearly impossible to make work from a practical point of view.

The second faulty premise is that these courts have elevated the generally held principle that public policy favors settlements above the statutory mechanisms that Congress put in place to encourage generic applicants to challenge weak patents and, hence, speed generic entry. This reasoning also lacks an appreciation of the view, as recently articulated by the U.S. Department of Justice Antitrust Division, that public policy also strongly favors ridding the economy of invalid patents, which impede efficient licensing, hinder competition, and undermine incentives for innovation.

Indeed, the industry experience under Hatch-Waxman between 1992 and 2000 shows that Congress struck the right balance when it established these incentives. During this period, generic challengers that had used paragraph IV certifications won their patent challenges in 73% of the cases. Indeed, these challenges have resulted in generic entry earlier than what otherwise would have occurred absent the generic challenge. These patent challenges and subsequent generic entry have yielded enormous benefits to consumers.

Although the FTC remains vigilant in searching for appropriate ways to take enforcement action against these types

of patent settlements, administrative law enforcement actions and appeals take several years to complete. During this time, consumers will be denied access to affordable drugs.

IV. Other Legislative Suggestions to Help Speed Generic Entry.

Congress also may wish to consider four specific actions so that consumers have access to safe and effective generic medicines in a timely manner. First, we urge Congress to address a way to break the bottleneck that occurs if the brand-name company does not sue a subsequent generic applicant. Under current law, there is no way to trigger a forfeiture of the first-filer's 180-day period, even through a subsequently filed generic drug application is ready to be approved. To address this issue, Consumers Union supports the FTC's recommendation for Congress to clarify that dismissal of a court action brought by a generic applicant seeking a declaratory judgment on patent infringement or invalidity constitutes a forfeiture event for the 180-day exclusivity period.

Second, there is no clear law providing for the development of generic versions of complex molecular biologic medicines. These new products are the most expensive medicines on the market—some costing as much as \$100,000 to \$250,000 for a course of treatment. Consumers Union believes that biogenerics could provide some savings and can be provided safely, thus helping some of our most severely ill patients. Existing FDA law should be clarified to allow the U.S. to do what the Europeans are doing: bringing some relief to consumers.

Third, we urge Congress to provide the FDA with sufficient resources to eliminate the backlogs in the approval of generics. In a memo to Consumers Union last autumn, the FDA reported that an unduplicated count of pending generic applications showed a backlog of 394 drugs pending more than 180 days—drugs which could help lower costs to consumers if they were approved.

Fourth, we urge Congress to stop the use of phony citizens petitions to delay generic entry. According to the FDA, only 3 of 42 petitions answered between 2001 and 2005 raised issues that merited changes in the agency's policies about a drug. For example, Flonase, a commonly used prescription allergy medication, went off-patent in May 2004. But GlaxoSmithKline stretched its monopoly window by almost two years with citizen petitions and a legal challenge to the use of generics. We recommend Congress end this abuse.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.